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THE ROLE OF SEMAPHORIN 5A IN PANCREATIC CANCER PROGRESSION
AND METASTASIS
Sugandha Saxena, Ph.D.
University of Nebraska Medical Center
Supervisor: Rakesh Singh, Ph.D.
This dissertation investigates the pathological significance and functional
role of Semaphorin 5A (SEMA5A), an axon guidance molecule, during Pancreatic
Cancer (PC) progression and metastasis. We analyzed the expression of SEMA5A
in human PC tissue and metastatic sites as well as in different PC progression
models

of

Pancreatic

Ductal

Adenocarcinoma

(PDAC)

and

Pancreatic

Neuroendocrine Tumors (PanNET). This study has identified upregulation of
SEMA5A in primary pancreatic tumors and metastases in comparison with the
normal pancreas. Furthermore, we examined the functional role of SEMA5A and
demonstrated that the upregulated secretory form of SEMA5A increases PC cell
migration, as well as enhances metastasis by acting as a ligand for the Plexin B3
receptor. We have also shown that SEMA5A enhances PC cell migration by
activating Met tyrosine kinase receptor. In addition, we made an attempt to
understand the function of endogenous SEMA5A expression in a PC cell by
generating knockdown of SEMA5A in different PC cell lines. Interestingly, we
observed that loss of SEMA5A increases cellular migration and enhances
metastasis by inducing Epithelial to Mesenchymal Transition (EMT). Furthermore,
ii

we demonstrate that upregulation of TGF2 secretion and non-canonical
activation of PI3K-AKT signaling may mediate this transition. Similar to loss of
SEMA5A, knockdown of Plexin B3 also induces a mesenchymal phenotype and
enhances metastasis, though not by inducing EMT. Together, these data
demonstrate that SEMA5A-Plexin B3 axis may play an important role in
maintaining an epithelial state of PC cells that limits the invasive capabilities of the
PC cell. Overall, the results presented in this dissertation reveal that SEMA5A
signaling can mediate both tumor-promoting roles by enhancing cellular migration
and angiogenesis and tumor inhibitory effects by maintaining the epithelial
phenotype and keeping invasion under check.
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Chapter 1
Introduction

1

I. The Significance of the Study:
Pancreatic cancer (PC) is a highly aggressive disease with poor survival.
The high mortality in PC patients is largely attributable to the late detection and
metastatic dissemination at the time of diagnosis. In the pursuit to improve the
clinical outcome of this disease, research focusing on targeting metastatic
dissemination is highly warranted. Several studies have established that axonal
guidance molecules, such as semaphorins (human: SEMA; mouse: Sema), are
mediators of angiogenesis, cellular migration, and metastasis in various cancers.
SEMA5A is a novel member of this family of proteins and has differential
expression in PC. However, the precise functional significance of SEMA5A and its
putative receptor Plexin B3 in PC metastasis remains unidentified. In this project,
we determined the significance of SEMA5A and its putative receptor Plexin B3 in
PC progression and metastasis by defining their pathological relevance and
mechanism of action. The results generated in this study will increase our
molecular understanding of new possible targets, which will ultimately aid in
overcoming the problem of PC metastasis in the future.
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II. Overview of the Normal Pancreas:
Anatomy:
The word “pancreas” means all flesh. The position of the human pancreas
is in the upper abdomen behind the stomach, and the pancreas has with a length
of 15-20 cm and weight around 100 grams (Longnecker, 2014). It is an elongated
gland with anatomical division into a head, body, and tail. The head of the pancreas
lies in the loop of the duodenum, the body of the pancreas crosses the midline of
the human body, and the tail lies near the hilum of the spleen. The designated
neck of the pancreas is the region that lies anterior to the superior mesenteric aorta
and is relatively thinner than the adjacent portions of the head and the body. The
neck is also in proximity to major blood vessels, including the superior mesentericartery, –portal vein, inferior vena cava, and abdominal aorta, which limits the option
of surgical margin during pancreatectomy. The common bile duct from the liver
and gallbladder passes through the head of the pancreas to join the main duct of
the pancreas (duct of Wirsung) near the duodenum. At the union of the pancreatic
duct and the common bile duct is present the ampulla of Vater, also known as the
hepatopancreatic duct, which is surrounded by the sphincter of Oddi. The valve of
the sphincter of Oddi regulates the flow of bile and pancreatic juice into the
duodenum and also prevents the reflux of intestinal contents into the pancreatic
duct.

3

Histology:
The pancreas has a thin layer of moderately dense connective tissue that
forms the capsule around the glands. From this capsule, septa extend into the
gland, dividing it into ill-defined lobules. There are two components of these
pancreatic lobules: the exocrine part with acinar glands and ducts, which
represents the bulk of the pancreas, and the endocrine part consisting of the Islets
of Langerhans embedded within this exocrine tissue. Exocrine pancreatic acini and
ducts form a complex tubular network. Endocrine Islets of Langerhans comprise
1-2% of the pancreas and are either spherical or ellipsoid in structure. The Islets
of Langerhans contains 20 % alpha () cells, around 70% beta (cells, 10% delta
(cells, less than 5% gamma () or pancreatic polypeptide (PP) cells, and less
than 1% epsilon () cells (Stefan et al., 1982). Near the acinar lobule are present
smaller sized Islets, while bigger sized islets are present along the main and
interlobular ducts of the pancreas.
Function:
The pancreas is an organ associated with the gastrointestinal system and
has a dual function. The exocrine portion of the pancreas produces and secretes
essential digestive enzymes into the duodenum, and the endocrine Islets of
Langerhans secretes hormones. The  cells produce glucagon,  cells produce
insulin, cells produce somatostatin, PP cells produce pancreatic polypeptide
(<5%), and cells produce ghrelin. The endocrine compartment of the pancreas is
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sufficiently vascularized, allowing for the effective functioning of the endocrine
organ.
III. PC:
Epidemiology:
PC is the growth of abnormal cells in the pancreas that leads to the
formation of a tumor. In comparison with other cancers such as lung, breast, and
prostate, the occurrence of PC is less common, yet PC remains one of the
deadliest cancers (Siegel et al., 2017). It is the fourth leading cause of cancerrelated deaths in United States of America and is projected to become the second
leading cause by the end of 2030 (Rahib et al., 2014). The American Cancer
Society estimates a total of 53,670 new cases and 43,090 deaths for both sexes
in the year 2017 (Siegel et al., 2017). The incidence of PC is more common in
older people than young and in males more than females. For the year 2017, the
estimated new cases for males and females are 27,970 and 25,700 respectively.
The estimated death numbers for each sex are 22,300 for males and 20,790 for
females. For all stages of PC combined, the one-year relative survival rate is 29%,
and the five-year rate is 7% (Fogel et al., 2017).
Even though the five-year survival rates have been improving for PC, the
disease is still considered largely incurable because of the lack of effective early
diagnostic tools and systemic therapies. In addition, another explanation of the
poor survival of PC patients is the fact that 53% of patients (all races) present
themselves with distant metastasis at the time of diagnosis. Therefore, one of the
5

major challenges in the field of PC is early detection at a stage where cancer has
not metastasized and surgical resection is possible. The recurrence of the disease
after surgery alone is common for PC, with over 50% of patients having a local
recurrence, and a majority of patients have a peritoneal or liver metastases (Kleeff
et al., 2007).
Risk Factors for PC Development:
Though our knowledge is still insufficient to identify the causes of PC,
people positive for factors such as smoking, obesity, genetic disorders and
mutations, diabetes, poor diet, and inactivity have been identified to be at higher
risk (Ilic and Ilic, 2016). The risk of developing PC increases with age, and more
than 50% of pancreatic adenocarcinomas occur in those over age 70. PC is more
common in men than women, and the American Cancer Society reports a higher
number of cases in the African-American population than in the Caucasian
population (Siegel et al., 2017). Meta-analysis studies report an association
between cigarette smoking and PC. Smokers are at 75 percent higher risk in
comparison with non-smokers, and this increased risk persists for at least ten
years after smoking cessation (Ilic and Ilic, 2016). Another meta-analysis of twentythree prospective studies of body mass index and PC risk reports that both general
and abdominal obesity increases PC risk (Aune et al., 2012). Individuals with
preexisting disease conditions like diabetes and pancreatitis, and individuals with
inherited genetic disorders such as Peutz-Jeghers syndrome, the hereditary
breast, ovarian cancer syndrome, and others have a higher chance of developing
6

PC. Lastly, individuals with mutations in specific genes, including K-RAS,
CDKN2A, TP53, PRSS1, and BRCA2, have an increased risk of developing PC
(Raimondi et al., 2009),(Ilic and Ilic, 2016).
Types of PC:
Classification of PC depends on the location of cancer in the pancreas and
the cell type of cancer initiation, as both the location and cell type affect the
functioning of the pancreas. There are two types of PC: exocrine and endocrine.
Two-thirds of PC begin in the head of the pancreas, while the remaining one-third
occur in the tail. Also, the vast majority of PC are exocrine in type, and although
uncommon, cancer can also begin in the specialized pancreatic endocrine cells
that produce hormones. The survival time of patients diagnosed with endocrine PC
is almost two years longer than those diagnosed with exocrine PC (Fesinmeyer et
al., 2005).
Tumors of the Exocrine Pancreas:
Exocrine PCs are mostly ductal adenocarcinomas that start in the cells
lining the ducts of the pancreas. Also, the less common types of exocrine PC
include cystic tumors that cause a cyst or fluid-filled sac in the pancreas, poor and
cancer of the acinar cells, which arises in the clusters of cells that produce
digestive enzymes. Other variants of adenocarcinoma include adenosquamous
carcinomas, colloid carcinomas, hepatoid carcinomas, medullary carcinoma,
signet ring cell carcinomas, undifferentiated carcinomas, and undifferentiated
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carcinomas with osteoclast-like giant cells (Hruban and Fukushima, 2007). The
solid pseudopapillary tumor is a rare low-grade neoplasm that mainly affects
younger women and has a very good prognosis (Shuja and Alkimawi, 2014).
Pancreaticoblastoma is another malignant pancreatic neoplasm that occurs
primarily in children 15 years and under (Chung et al., 2006).
PDAC results in blockage of the pancreatic duct, which may be a causative
factor for jaundice and cachexia and can serve as an apparent explanation of
higher fatality rate of exocrine tumors (Hruban and Fukushima, 2007). PDAC are
virulent in nature, as at the time of diagnosis, the tumor cells have already
metastasized to distant organs. Thus, to diagnose this disease early, it becomes
important to study the precursors of ductal adenocarcinoma, which are pancreatic
intraepithelial neoplasias

(PanINs), intraductal papillary mucinous cystic

neoplasms (IPMNs) and mucinous cystic neoplasms (MCNs) (Hruban et al., 2007)
PanINs are microscopic neoplastic clusters of proliferating epithelial cells in
pancreatic ducts that can be subdivided into PanIN grades 1-3. A study of PanINs
suggests the possibility of a diagnosis of PC at a non-invasive stage and before
the development of invasive cancer (Hruban and Fukushima, 2007). PanINs
involve epithelial cells producing mucin with varying degrees of cytological and
architectural atypia involving the small ducts of the pancreas. PanINs starts with
normal cells with cuboidal to the low columnar epithelium. In squamous or
transitional metaplasia, the cuboidal ductal epithelium is replaced by stratified or
pseudostratified transitional epithelium without atypia. PanIN-1A are flat epithelial
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lesions consisting of tall columnar cells with abundant mucin production. PanIN1B are similar to PanIN-1A with papillary architecture. PanIN-2 are mostly papillary
with some nuclear abnormalities, followed by PanIN-3 with marked cytological
abnormalities, true cirbriforming, budding off of epithelial cells and luminal necrosis
(Hruban et al., 2007). PanIN-3 lesions resemble infiltrating ductal carcinoma with
no invasion through the basement membrane. These PanIN types can progress
from one type to the other.
MCNs, comprised of tall columnar epithelial cells producing mucin, do not
involve the duct system of the pancreas and are grossly visible neoplasms. MCNs
also progress from dysplasia to in situ carcinoma to invasive adenocarcinoma.
MCNs are mostly prevalent in women whereas PanINs occur in both women and
men (Matthaei et al., 2011). The location of MCN is in the body and tail of the
pancreas.
IPMNs grow in larger native ducts of the pancreas as mucinous and villous
neoplasms. Like PanINs, IPMNs have various types, and they progress from one
type to the other – intraductal papillary mucinous adenomas, borderline IPMN and
intraductal papillary mucinous neoplasm with carcinoma in situ. IPMN is in the
head of the pancreas with the characteristic frequent mutation in codon 12 of the
K-ras oncogene (Grützmann et al., 2010).
Tumors of the Endocrine Pancreas:
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Endocrine tumors are rare and start in the islet cells and are called islet cell
tumors or PanNETS (Longnecker, 2014). Nomenclature of these tumors is
according to the hormone they overproduce. They are sub-classified into
insulinoma, glucagonoma, somatostatinoma, or nonfunctional islet cell tumors.
Difficulties in PC Therapy:
PC and liver cancer are two typically fatal malignancies. Problems faced by
PC researchers are innumerable, making this cancer one of the most difficult to
treat. Early diagnostic examination is not possible due to the retroperitoneal
position of the pancreas. Diagnosis of some other cancers, like skin cancer, is
possible through external visualization; external palpation for breast cancer,
internal visualization during PAP smears can detect cervical cancers, screening by
digital rectal examination or prostate-specific antigen can diagnose prostate
cancer, and colonoscopy can find colorectal cancers (Kaur et al., 2012). Also,
detection of the tumor is hindered by intense desmoplasia with a dense
extracellular matrix (ECM), stellate cells, immune cells, and other cells, limiting the
detection of factors secreted by the tumors.
Symptoms of PC are generic, including abdominal or back pain, weight loss,
jaundice (yellowing of skin and eyes), loss of appetite, nausea, light stool color,
and diabetes. Moreover, most patients do not develop symptoms until the cancer
has metastasized. At the time of diagnosis, only 20% of the patients are surgical
candidates with tumors localized in the pancreas. Of the remainder of the patients,
half present themselves with the locally advanced disease with tumors spread to
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nearby organs, and the other remainder half have rapidly progressing metastatic
PC (Li et al., 2010). The aggressive nature of PC leads to multiple levels of therapy
resistance, and clinical trial efforts to improve current regimens fail drastically for
advanced stages of PC. In general, it is difficult to distinguish between a benign
reactive gland of chronic pancreatitis and an infiltrating gland of well-differentiated
PC. Chronic pancreatitis and PC differ significantly with outcome regarding life
expectancy and treatment (Hruban and Fukushima, 2007).
Clinical Management of PC:
A comprehensive analysis of the extent of PC reveals that most patients fall
into one of three clinical stages: resectable, unresectable, and metastatic PC.
Clinical stage and disease resectability are the major determinants of the treatment
and

clinical

management

of

PC.

Treatment

options

include

surgery,

chemotherapy, and radiation. The modality and sequence depend on the clinical
stage of the disease (Reynolds and Folloder, 2014). Whipple operation or
pancreaticoduodenectomy (when the location of the tumor is in the head of the
pancreas) and distal pancreatectomy with splenectomy (when the location of the
tumor is in the body or tail of the pancreas) are two types of surgery performed for
PC. Gemcitabine and fluorouracil are the primary chemotherapeutic agents used
for PC.
For resectable PC, it is recommended to proceed immediately with surgery
followed by adjuvant therapy. However, some centers recommend the use of
neoadjuvant therapy that is the use of radiation and chemotherapy before surgery
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(Reynolds and Folloder, 2014). Borderline resectable PC is a recent new category
of resectable tumor that is regarded as heterogeneous, and which is treated with
combination therapy like FLOFIRINOX (a combination of fluorouracil, oxaliplatin,
irinotecan, and leucovorin) followed by radiation (Reynolds and Folloder, 2014).
Locally advanced tumors and metastatic PC are considered unresectable and
therefore incurable. This stage has no option for resection and treatment usually
consists of systemic chemotherapy or radiation. Survival of metastatic PC patients
is less than a year with a poor response to chemotherapy. Therefore, the goal of
treatment is to provide relief of their symptoms and improve the quality of life.
Future Therapeutic Options:
Several promising therapeutic avenues for patients with locally advanced
and metastatic PC are under development. Efforts are under way to identify targets
that can discriminate early or late-stage cancer. Among the most promising targets
is a peptide that is upregulated in PanIN 3 carcinomas and recognizes the
extracellular expression of Plectin-1 (Bausch et al., 2009; Kelly et al., 2008;
Oberstein and Olive, 2013).
New therapeutic avenues for patients with advanced or metastatic PC are
being explored. A variety of approaches has been taken to target components of
the pancreatic tumor stroma. To facilitate the delivery of drugs like gemcitabine to
pancreatic tumors, a modified enzyme PEGPH20, which breaks down hyaluronan
crosslinks in the extracellular matrix, is in clinical trials (Jacobetz et al., 2013;
Oberstein and Olive, 2013; Provenzano et al., 2012). Two agents (gamma12

secretase inhibitor RO4929097 and a potent DNA alkylator TH-302) that take
advantage of the paucity of the vasculature in PC are also in clinical trials (Cook
et al., 2012; Von Hoff et al., 2011). Recently, after an encouraging phase II study,
the phase III study of gemcitabine with a nanoparticle reformulation of taxol
(Abraxane), confirmed this therapy to be a new tool for the treatment of PC patients
(Von Hoff et al., 2011). Finally, two novel immunotherapy approaches, anti-GMCSF antibodies, and a CD40 agonist in combination with gemcitabine are under
development for PC (Bayne et al., 2012; Oberstein and Olive, 2013; PylayevaGupta et al., 2012).
IV. Metastasis:
Definition and Early Ideas:
Metastasis is the process in which cancer cells migrate from the primary
site of origin to nearby areas or distant sites to establish secondary growth of tumor
cells. As described earlier, metastases or the consequences of their treatment are
significant contributors to cancer death, and more than 40% of patients present
with metastatic PC at the time of diagnosis (Li et al., 2010). Despite improvements
in the treatment of a resectable tumor, metastasis is the driver of mortality.
Metastasis produced by different cancers is predictable, and hence
oncologists believe that it is not a random process (Comen, 2012). Mechanisms of
the process of metastasis came through many historically accepted models. In the
early 19th century, Campbell Greig De Morgan proposed that cancer cells linearly
progress from the primary tumor to lymph nodes and then to distant sites. In 1889,
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Stephen Paget further explained the principle of metastasis in his “seed and soil
hypothesis” stating, “When a plant goes to seed, its seeds are carried in all
directions; but they can only live on congenial soil.” Thus, there are two
components in the establishment of metastasis: the selected metastatic cell (seed)
and the unique organ environment (soil) (Fidler and Kripke, 2015).
In the mid-20th century, scientists elaborated that the spread of cancer cells
can occur not only through lymphatic dissemination but also through
hematogenous

dissemination

(Comen,

2012).

Furthermore,

researchers

demonstrated a disconnect between tumor size and nodal status, showing that
small tumors may have greater than expected lymph node involvement versus
large tumors with no lymph node involvement. This observation reflects the
inherent difference in the ability of a tumor cell to metastasize.
Larry Norton and Joan Massague (Comen et al., 2011) developed the
theory of “self-seeding” suggesting a multi-directional nature of cancer spread that
can seed distant sites as well as primary tumor itself.
The Invasion-Metastatic Cascade:
Metastases are the result of the successful completion of multistep
biological events known as the invasion-metastasis cascade (Valastyan and
Weinberg, 2011; Vanharanta and Massague, 2013). The details of each step in
this cascade are the following. First, local invasion occurs, which involves entry of
cancer cells from a well-defined tumor boundary into the surrounding tumor
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stroma. This entry provides abundant opportunities for invading tumor cells to
access the systemic circulation and thereby disseminate to secondary sites. The
second step following local invasion is intravasation, which is the entry of invasive
cancer cells into the lumen of lymphatic or blood vessels. Hematogenous
circulation is the major route for tumor cell dissemination (Gupta and Massague,
2006). Tumor cells can also stimulate neovascularization (formation of new blood
vessels). These newly generated blood vessels, characterized by weak
interactions between adjacent cells and insufficient coverage by pericytes,
facilitate the process of intravasation (Carmeliet and Jain, 2011b).
After the successful intravasation of tumor cells, their survival ability in the
circulation is tested (Valastyan and Weinberg, 2011). These cells face a variety of
stresses like detachment from the ECM, hemodynamic shear force, and predation
by cells of the innate immune system. Once cells have survived this part of their
journey, they arrest at a distant organ site. Whether this arrest is due to the layout
and size restriction of the vasculature or homing of these cells to the specific organ
as a result of interaction between tumor cells and the luminal walls of the
vasculature needs further investigation. The cells must then extravasate, which
can either involve microcolony growth (which ruptures the wall of the surrounding
vessels), or cells cross the vessel by penetrating through the endothelial cells and
pericytes. These extravasated cells must survive at the distant site to form
micrometastases.
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For survival, cancer cells must adapt themselves to the microenvironmental
differences found at the metastatic locus in comparison with the primary site such
as the ECM and the availability of necessary growth factors or cytokines.
(Valastyan and Weinberg, 2011). Recent studies indicate that cancer cells can
address the issue of a differing microenvironment at the metastatic site via the
establishment of a “premetastatic niche” (Liu and Cao, 2016). After successful
survival of cancer cells in the foreign microenvironment, reinitiation of cancer cell
proliferation is necessary for the formation of macrometastasis. Evidence suggests
that one or more of the steps of the invasion-metastasis cascade are rarely
completed successfully, thereby making the process of metastasis a highly
inefficient one. Despite the inefficient nature of this process, many cancer cells can
establish themselves as metastases thereby suggesting the importance of
understanding the source of such cells and the sites which drive successful
colonization of such cells (Vanharanta and Massague, 2013). A pictorial
representation of metastatic invasion cascade is shown in Figure 1.1.
Models of PC Metastasis:
There are two primary fundamental models to explain metastasis (Klein,
2009; Rhim et al., 2012): early dissemination (parallel progression) and late
dissemination (linear progression), as reviewed by Das and Batra (Das and Batra,
2015). The parallel progression model proposes early dissemination of tumor cells
at a stage even before the formation of a primary tumor. In this model, parallel
development of the primary tumor and metastases takes place; thereby each
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undergoes different genetic and epigenetic alterations. This model explains clinical
observations that most patients die of the metastatic disease within 5-years postprimary PC resection with no margins or evidence of metastasis at the time of
pancreatic tumor surgery (Das and Batra, 2015). Another line of evidence comes
from a study using a mathematical model to predict the existence of cells that are
capable of establishing metastasis even when the size of the primary tumor is
small (Haeno et al., 2012). Lastly, a study using lineage tracing in a genetically
engineered mouse model demonstrated that the tumor cells from PanIN-2 and -3
stages were able to cross the basement membrane of the pancreas and seed
themselves in the liver (Rhim et al., 2012).
The linear progression model proposes the development of metastasis as
an evolutionary process. The tumor cells undergo successive rounds of mutations
and selection at the primary site before being deemed fit to be disseminated for
metastatic colonization (Das and Batra, 2015). According to this model, the genetic
alterations in the primary tumor and metastases are similar. Metastasis is
considered to be a very late event in this evolutionary process, and the efficiency
of dissemination is proportional to primary tumor size. Recent high-resolution
genetic studies showed similar genetic alterations in metastases and their
corresponding primary tumor suggesting that metastasis is a late event during the
evolution of PC (Campbell et al., 2010). Another study using high-throughput
sequencing information proposed a timescale for the initiating mutation, to the
emergence of a non-metastatic parental clone, and the establishment of the
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metastatic subclones. This time scale fits well with the late dissemination model of
metastasis (Yachida et al., 2010). However, for critical evaluation of these models
of metastatic dissemination, further basic and translational studies are needed.
Targeting Metastasis:
Identification of metastasis-related druggable targets lags far behind
regarding clinical trials and therapies for the standard of care. Most of the
metastasis-directed therapies in preclinical experiments are cytostatic and not
cytotoxic, thereby limiting their clinical validation (Steeg, 2016). Thus, there is an
urgent need to develop new targets that can lower the metastasis-driven mortality
rate.
Targeting a cancer cell is difficult because of the problem of genetic
instability and heterogeneity (Fidler and Kripke, 2015). Genomic instability enables
new variants to arise rapidly leading to therapy resistance. Moreover, primary
tumors as well as metastases are heterogeneous in nature. Diverse properties like
gene expression, growth rate, marker enzymes, sensitivity to different cytotoxic
drugs, and others make the choice of target difficult. On the other hand, targeting
the receptive organ-microenvironment represents a stable target. Also, just
prevention of metastasis is not enough since dissemination of tumor cells may
occur before surgical resection of the primary tumor. At best, such approaches will
only prevent the further development of secondary metastases. Therefore, to
address the major challenge of treating existing metastases, the simultaneous
targeting of cancer cells along with the distant organ microenvironment is more
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likely to produce better therapeutic results than solely targeting the metastatic cell
or the organ microenvironment.
Our emerging understanding of the metastatic cascade will lead to the
identification of new druggable targets (Steeg, 2016). The entire metastatic
cascade represents potential therapeutic targets for patients with a localized
tumor. However, in a malignancy like PC with limited cases of a localized tumor,
the last step of metastatic colonization represents an attractive therapeutic target.
Interruption of metastatic colonization could prevent the formation of additional
metastases. Metastatic tumor cells undergo the process of mesenchymal–
epithelial transition (MET) during colonization (discussed in detail in the next
section). Targeting cellular programs which control this transition may represent
an attractive therapeutic opportunity in metastasis.
V. Epithelial to Mesenchymal Transition (EMT):
In early 1980, Elizabeth Hay observed the changes in epithelial to
mesenchymal phenotype in the primitive streak of chick embryos and described it
as epithelial to mesenchymal transformation (Hay, 1995). However, to emphasize
the transient nature, this process is now commonly known as epithelial–
mesenchymal transition (Lamouille et al., 2014).
Epithelial and mesenchymal cells represent two cell types in metazoans
with differences in morphogenesis and functions (Acloque et al., 2009). Epithelial
cells have a defined structure with apical-basal polarity and a characteristic basally
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localized basement membrane. Epithelial cells closely attach to their neighboring
cell by intercellular adhesion complexes (tight junctions, adherens junctions,
desmosomes, and gap junctions). They also attach to the basement membrane by
cell-matrix anchoring junctions. On the contrary, mesenchymal cells are
nonpolarized in structure and lack intercellular junctions. They are spindle shape
in structure and have characteristic leading and trailing edges. This morphology
aids their motility and invasiveness throughout the ECM. A general pictorial
representation of cells undergoing EMT transition is shown in Figure 1.2.
Whether epithelial or mesenchymal, all cells in the body ultimately derive
themselves from a single cell, the fertilized egg. During development, these cells
can assume various phenotypic states by undergoing the process of differentiation
(Kalluri, 2009; Kalluri and Weinberg, 2009). A state of terminal differentiation is
necessary to carry out specialized functions of the body. However, only during
specific steps of embryogenesis and development do these cells appear to be
plastic and able to move back and forth between epithelial and mesenchymal
states by the processes of EMT and MET. However, in adults conditions like a
tissue injury and initiation of the invasive and metastatic behavior of epithelial
cancers challenged this idea. Under these conditions, a terminally differentiated
epithelium

changes

its

phenotype

to

mesenchymal

transdifferentiation through activation of an EMT program.
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by

undergoing

Types of EMTs:
The decision of the classification of EMT into three biological subtypes took
place in the meeting on EMT in Poland (2007) followed by the meeting at Cold
Spring Harbor Laboratories (2008) (Kalluri, 2009). Distinct biological settings and
their functional outcomes form the basis of classification. Type 1 EMT is involved
in processes like embryo implantation, formation, and organ development. This
class of EMT generates diverse cell types that share common mesenchymal
phenotypes that have the potential to undergo MET and generate secondary
epithelia subsequently. Type II EMT occurs in processes like wound healing, tissue
regeneration, and organ fibrosis. This EMT begins as part of a tissue repair
process and generates fibroblasts and other related cells to reconstruct tissues.
Type 3 EMT occurs in neoplastic cells that have previously undergone genetic and
epigenetic changes. These cancer cells undergo a type 3 EMT to invade and
metastasize to nearby and distant organs. These three classes of EMT represent
distinct biological processes, and with more experimentation in the future, we will
learn more regarding the similarities and differences among the three classes of
EMTs.
EMT, MET, and Metastasis:
During EMT, epithelial cells lose their junctions and apical–basal polarity,
reorganize their cytoskeleton, undergo a change in the signaling programs that
define cell shape and reprogram gene expression; this increases the motility of
individual cells and enables the development of an invasive phenotype (Lamouille
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et al., 2014). The gain of a more mesenchymal phenotype aids different steps of
the metastatic cascade like local invasion, intravasation, systemic circulation, and
extravasation (Tsai and Yang, 2013). Hence, activation of an EMT program is
considered critical for the acquisition of malignant phenotypes by epithelial cancer
cells.
Interestingly, at the histopathological level, colonies at distant sites
resemble the primary tumor from which they arose. This observation suggests that
before establishing themselves as secondary tumors, migratory cancer cells must
shed their mesenchymal phenotype by undergoing the process of MET. After
undergoing extravasation, the encounter with the microenvironment at a distant
organ can be a reason for disseminated cancer cells to undergo MET (Tse and
Kalluri, 2007). Thus, induction of EMT during the progression of cancer and
subsequent MET during the colonization process represents a centrally important
mechanism for the process of metastasis (Heerboth et al., 2015).
Molecular Program of EMT:
The process of EMT requires the cooperation of a large number of
molecular signaling pathways and regulators to undergo the complex
morphological and cellular transition. There are three groups of EMT mediators
classified by their function. First, EMT effectors are the molecules that execute the
EMT program. Second, EMT core regulators are the transcription factors that
orchestrate the EMT program, and last, EMT inducers are the extracellular cues
that activate the EMT program.
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EMT effectors are proteins that distinguish between the identity of the
epithelial or mesenchymal cell. For example, key molecular components of
structures like junctional complexes in epithelial cells are down-regulated at the
RNA and protein levels (Zeisberg and Neilson, 2009). Among them, E-cadherin
(E-cad) is a hallmark of the epithelial state in various epithelial cell types. Other
molecules include -catenin, -catenin, claudins and others. Furthermore, a switch
from cytokeratin to vimentin occurs during EMT. The increase in vimentin levels is
also a consistent marker for the mesenchymal phenotype. Additional EMT effector
molecules are proteins that promote cell migration and invasion such as
fibronectin. Some nonepithelial cadherins, such as N-cadherin (N-cad) are induced
and thought to be critical for proper cell migration.
EMT core regulators involve the transcriptional alteration of many genes
regulating cell migration, cell adhesion, mesenchymal differentiation, and invasion.
Three core groups of transcriptional factors constitute the family of the core EMT
regulators: the Snail zinc finger family, the distantly related Zeb zinc finger family
and the Twist basic helix–loop–helix family (Moreno-Bueno et al., 2008).
EMT inducers are the extracellular signals in the tumor microenvironment
that activate the EMT program in cancer cells. All major developmental signaling
pathways, including TGF, Wnt, Notch, and growth factor receptor, are linked to
activation of the EMT program (Tsai and Yang, 2013). Most notably, the TGF
pathway appears to be a primary inducer of EMT (Katsuno et al., 2013). Also,
many EMT-inducing signals are either cell type- or tissue type-specific and
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probably require the cooperation between multiple pathways. Cooperation or
crosstalk between signaling pathways in EMT is quite common and is observed in
vivo as well as in vitro (Lamouille et al., 2014).
VI. Semaphorins in Cancer:
Introduction and Classification:
The term semaphorin derives its root from the word “semaphore”- a system
of sending visual signals using flags (Goodman CS, 1999). Semaphorins represent
the largest family of the guidance cue ligand molecules. Along with their cognate
receptors, semaphorins regulate axonal and dendritic growth during embryonic
development. Semaphorins were originally named “collapsins” for their roles in the
collapse of neuronal growth cones (Luo et al., 1993). Various cells other than
neurons are also positive for the expression of semaphorin receptors. Thus,
semaphorins

also

regulate

non-neuronal

processes

like

cardiovascular

development (Epstein et al., 2015), vasculogenesis (Gu and Giraudo, 2013), and
also the functions of the immune system (Suzuki et al., 2008). Interestingly, recent
literature suggests a role for semaphorins in pathological processes like
angiogenesis, tumor growth and metastasis (Capparuccia and Tamagnone, 2009;
Neufeld and Kessler, 2008; Neufeld et al., 2016).
Structural similarities, species of origin and the presence of class specific
carboxy-terminal domains form the basis for the classification of semaphorins. This
family has thirty proteins (21 vertebrate, eight invertebrate and one viral)
distributed into eight classes (Neufeld and Kessler, 2008). A general pictorial
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representation of Semaphorin family members is shown in Figure 1.3. Fasciclin IV
in grasshoppers was the first identified semaphorin (Kolodkin et al., 1992).
Semaphorins are characterized by a conserved sema domain which is necessary
for their binding to the cognate receptors (Kolodkin et al., 1993). The sema domain
is a seven blade beta propeller, similar to alpha integrins, with around 500 amino
acids in the N-terminal region (Gherardi et al., 2004). Semaphorins, plexins and
Met, and Ron receptor tyrosine kinases share the “sema” domain (Gherardi et al.,
2004). A MET-related sequence (shares homology with the Met subfamily of
tyrosine kinase receptor) or PSI domain (found in plexins, semaphorins, and
integrins) is a cysteine-rich domain (CRD) present next to the sema domain at its
terminal end (Kozlov et al., 2004). Apart from common sema and PSI domains,
each class has a unique feature. Class 2-5 and class 7 semaphorins have the CRD
domain followed by one immunoglobulin domain, which is absent in class 6
semaphorin proteins. Class 5 semaphorins are unique in having thrombospondin
(TSP 1) repeats (Adams and Lawler, 1993; Adams et al., 1996). Semaphorins can
either be secreted (class 2, 3 and 5) or membrane-bound (class 1, 4-7) in nature.
The membrane-bound Semaphorins can either be transmembrane (class1, 4-6) or
membrane-anchored (class 7) via glycosylphosphatidylinositol sequences
(Tamagnone and Comoglio, 2000).
Receptors for Semaphorins:
There are two specific receptors for semaphorins: plexins and neuropilins
(NRPs). Plexins are the receptor for membrane-bound semaphorins, whereas
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plexins along with NRPs as co-receptors are receptors for secreted semaphorins
(Zhou et al., 2008) (Fig. 1.4).
Plexins: There are four subfamilies of plexins in vertebrates named A, B, C
and D and only two plexin proteins in invertebrates (Takahashi and Strittmatter,
2001). Subfamily A has four (A 1-4) members, subfamily B has three (B 1-3), and
subfamily C and D have one member each. Similar to semaphorins, plexins also
contain a sema and a CRD domain in their extracellular region. The sema domain
has an auto-inhibitory effect on the plexin receptor and prevents the activation of
the receptor in the absence of the ligand (Takahashi and Strittmatter, 2001).
Plexins have three CRD domains and three immunoglobulin-like domains called
immunoglobulin-like plexin transcription factor domains in the extracellular region.
The intracellular region of plexins consists of two highly conserved domains with
striking similarity to GTPase activating proteins (GAP like domains). A linker
domain is present in between these conserved domains that interacts with GTPbound monomeric GTPases of the Rho family. In addition to the above domains,
Class B plexins also have a C-terminal consensus sequence that interacts with
PDZ domains. Plexins are either membrane bound or secretory in nature. A
general pictorial representation of Plexin structure and family members is shown
in Figure 1.4. They can mediate autocrine or paracrine signaling by binding to their
respective semaphorin and can act as ligands as well as receptors for
semaphorins. Furthermore, they can either mediate signaling alone or with their
co-receptors, NRPs (Zhou et al., 2008).
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NRPs: There are two members of this family of proteins, NRP1 and NRP2.
They are membrane bound as well as soluble molecules of 120 to 130 kDa
molecular weight and can have multiple isoforms (Neufeld et al., 2002). NRPs
contain a CUB a1/a2 domain which can bind to the sema domain as well as two
coagulation factor V/VIII homology domains b1 and b2 which are known to bind to
vascular endothelial growth factor (VEGF). Following these are a meprin domain
(involved in protein dimerization), a transmembrane domain, and a short
cytoplasmic domain a transmembrane domain and a short cytoplasmic domain
(Neufeld et al., 2002; Soker et al., 1996). A general pictorial representation of NRP
structure is shown in Figure 1.4. Like the plexin class B family, NRPs also contains
a PDZ domain that binds to the PDZ domain of NRP-interacting proteins to initiate
signaling. NRPs cannot signal themselves due to the absence of a kinase motif
and a short cytoplasmic tail (Ellis, 2006). They signal by forming complexes with
plexins or VEGF receptors depending on whether the interacting partner is
semaphorins or VEGFs respectively. NRPs are known to have bifunctional activity,
i.e. they inhibit angiogenesis and tumor progression by interacting with
semaphorins or enhance them by interacting with angiogenic VEGF ligands. More
research is required to understand the role of NRPs as binding partners of
semaphorins.
Diverse Signaling of Semaphorins:
Semaphorins, whether secreted or membrane-bound, are known to form
dimers to fulfill their functional activity (Artigiani et al., 2004; Janssen et al., 2010;
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Oster et al., 2003). The sema domains of semaphorin and plexin molecules
interact with each other in a trans-manner to trigger signaling (Rizzolio and
Tamagnone, 2007). Semaphorin dimers bind independently to two plexin
molecules which stabilize the plexin dimerization for initiation of downstream
signaling (Janssen et al., 2010; Zhou et al., 2008). However, secreted
semaphorins (Class 3) interact with NRPs first to form complexes with plexins and
initiate downstream signaling.
Semaphorin signaling through plexins is “forward” signaling. Semaphorins
can initiate various signaling cascades upon binding with their cognate plexin
receptors resulting in diverse cellular effects (Battistini and Tamagnone, 2016;
Capparuccia and Tamagnone, 2009). The intracellular domain of Plexin molecule
in itself lacks kinase activity. For signaling, plexins can also interact with different
tyrosine kinases such as Met, receptor tyrosine-protein kinase erbB-2 (ERBB2), or
Src, which may elicit different functional outcomes depending upon the type of
cells. Plexins upon interaction with receptor, as well as cellular tyrosine kinases
can initiate downstream signaling either by phosphorylating themselves
(Phosphatidylinositol-4,5-bisphosphate 3-kinase (PI3K)/ Protein Kinase B (AKT)
pathway) or by phosphorylating the tyrosine residues on the cytoplasmic GAP
domains of plexins. Phosphorylation of the GAP domain can elicit different
effectors like RAS or Rho that can control integrin activation and cytoskeletal
dynamics respectively. Forward signaling eventually influences cell migration.
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On the other hand, transmembrane semaphorins can not only act as ligands
but receptors as well. Initiation of a signaling cascade through a semaphorin’s own
cytoplasmic domain is called "reverse" signaling (Battistini and Tamagnone, 2016).
Semaphorin 1a, which controls motor axon defasciculation and target recognition
during neuromuscular development in Drosophila, is an example of reverse
signaling (Jeong et al., 2012). Other examples of reverse signaling are class-6
semaphorins, the most similar vertebrate member to invertebrate semaphorin 1a,
and class-4 semaphorins containing a cytoplasmic PDZ domain (Burkhardt et al.,
2005).
Lastly, semaphorins and plexins can interact not only in a transmanner but
also in a cis manner, adding another layer of diverse possible signaling outputs
(Battistini and Tamagnone, 2016). These various signaling abilities of
transmembrane semaphorins are already known to play multifaceted roles in
developmental processes. More experimentation is required to understand this
multifaceted signaling in pathological conditions like cancer. Diverse signaling of
semaphorins is shown in a schematic in Figure 1.5.
The Parallel Roles of Semaphorins in the Nervous System and Cancer Biology:
Semaphorins affect the biology of cancer progression by playing critical
roles in pathological angiogenesis and metastatic dissemination of cancer cells
(Neufeld and Kessler, 2008; Neufeld et al., 2012; Rehman and Tamagnone, 2013).
Semaphorins are bifunctional guidance cue ligands that help growing neurons
follow the right developmental path. Similarly, the process of angiogenesis is also
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regulated by navigational cues that guide the growth cones of endothelial tip cells
(Carmeliet and Jain, 2011a; Eichmann et al., 2005). Recent evidence suggests
that semaphorins can act as pro/antiangiogenic factors. Disturbance in the balance
of these factors can disrupt the network precision resulting in pathological
conditions (Rehman and Tamagnone, 2013).
The gain of migratory ability and the guidance of migrating cells to the
secondary site are also critical events for the establishment of metastasis.
Interaction of a cell with a guidance cue commands a cell to move. This interaction
initiates a series of molecular events that either make the cell move forward or
hinder it. Likewise, the movement of cells during pathological conditions like
metastasis is also mediated by similar cytoskeletal attraction and repulsion
changes (Adams et al., 1996; Tran et al., 2007). A growing body of evidence now
supports the roles of various semaphorins as cues necessary for angiogenesis,
cellular migration (Basile et al., 2006; Sadanandam et al., 2012; Tseng et al.,
2011), and organ-specific homing of cancer cells (Sadanandam et al., 2007).
VII. Class 5 Semaphorins:
Structure:
There are three members of the class 5 semaphorin family: SEMA/Sema5
A, B, and C. SEMA5A and Semaphorin 5B are the vertebrate members whereas
sema5c is an invertebrate member found in Drosophila (Bahri et al., 2001). The
vertebrate members were initially identified in murine embryos as semF (SEMA5A)
and semG (Semaphorin 5B) (Adams et al., 1996). In 1999, the semaphorin
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nomenclature committee renamed SemF as Sema5A (mouse)/ SEMA5A under
the unified nomenclature system (Goodman CS, 1999). SEMA5Awas found to
span chromosome 5p15. SEMA5A is an integral membrane protein, with a
characteristic 408 amino acid “thrombospondin repeat” domain apart from its
conserved N-terminus sema domain in its extracellular region (Adams et al., 1996).
Thrombospondin repeats promote attachment of various cells to ECM substrates
and play growth-promoting roles.
SEMA5A in Cancer:
Recently, many reports suggest the role of SEMA5A in the pathobiology of
cancer. The first evidence for SEMA5A in cancer came from a study on
leiomyomata, a benign smooth muscle neoplasm of the uterus (Tsibris et al.,
2002). Microarray data on patient samples demonstrated upregulation of SEMA5A
in leiomyomata in comparison to the control myometrium. Later, in a Drosophila
screening study aimed at the identification of genes essential in tumorigenicity and
metastasis showed a functional role for sema5c (a Drosophila homolog of
Sema5A) in the development of a cancer phenotype (Woodhouse et al., 2003).
The role of SEMA5A in PC is described separately in the following section.
A study on gastric carcinoma patients reported elevated SEMA5A
expression in primary gastric carcinoma and lymph node metastasis in comparison
with non-neoplastic tissue (Pan et al., 2009). Also, SEMA5A knockdown in
SGC7901 gastric carcinoma cells showed enhanced apoptosis and inhibition of in
vitro invasiveness (Pan et al., 2010). This group further demonstrated that
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SEMA5A activates the MEK/ERK pathway leading to the up-regulation of matrix
metallopeptidase 9 (MMP9) (Pan et al., 2013). In contrary to the case of gastric
carcinoma, reports demonstrate reduced expression of SEMA5A in clinical
samples of high-grade astrocytomas compared to the normal brain (Li and Lee,
2010). Li et al. delineated mechanistic changes inside the glioma cells suggesting
that SEMA5A inhibits the motility of glioma cells (Li et al., 2012b). In summary,
these findings support the role of SEMA5A as a tumor suppressor in glioma.
Similar observations were reported for lung cancer where lower expression of
SEMA5A was associated with poor overall survival in female, non-smoking lung
cancer patients in Taiwan (Lu et al., 2010).
Together these data do not define an unequivocal role for SEMA5A in
cancer. Rather, SEMA5A can act as a tumor suppressor or a tumor promoter,
depending on the type of cancer. One of the reasons for these observations could
be the interaction of SEMA5A with different receptors which can stimulate diverse
pathways in a cell-specific manner.
SEMA5A in PC:
We identified SEMA5A, a putative cell adhesion molecule, to be involved in
organ-specific PC metastasis using an in vivo phage display library and integrated
computational analysis (Sadanandam et al., 2007). Validation of our in silico
results was performed using RT-PCR analysis on nine human PC cell lines,
derived from either primary tumors or metastases (Sadanandam et al., 2010b); the
first report to demonstrate the expression of SEMA5A in PC. SEMA5A expression
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was found to be higher in moderately or well differentiated human pancreatic
tissues than the normal pancreas and poorly/undifferentiated tumors. Interestingly,
SEMA5A has higher expression in cell lines derived from metastases in
comparison with primary tumors, suggesting its role in the metastatic progression
of this disease. Furthermore, Plexin B3 was identified as a binding partner for
SEMA5A, using computational analysis as well as by immunoprecipitation assay
in various mouse tissues (Sadanandam et al., 2008).
In order to determine the effect of SEMA5A on PC tumorigenesis and
metastasis, SEMA5A was overexpressed in the Panc1 cell line. The tumorigenic
potential of SEMA5A in PC was validated by in vitro and in vivo assays. Panc1SEMA5A resulted in increased tumorigenesis and enhanced metastasis to distant
organs like liver, lymph node, spleen and peritoneum when implanted
orthotopically into nude mice (Sadanandam et al., 2010b). Furthermore, in another
study, Panc1 cells were transfected with the extracellular domain (ECD) of
SEMA5A to analyze its role in tumor progression and metastasis, and Panc1
Sema5A-ECD cells showed higher metastatic potentials both in vitro and in vivo.
These findings demonstrate the importance of SEMA5A in PC metastasis
(Sadanandam et al., 2012).
Further experimentation was carried out to determine the effect of SEMA5A
in PC. Initial evidence for the role of SEMA5A in pathological angiogenesis came
from the defective patterning of the cranial vasculature in SEMA5A null mice (Fiore
et al., 2005). Endothelial cells were treated with recombinant Sema5A-ECD, and
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enhanced proliferation of endothelial cells was observed which was found to be
mediated through Plexin B3 (Sadanandam et al., 2010a). Furthermore, endothelial
cells treated with Sema5A-ECD secreted proangiogenic factors like VEGF and
interleukin-8. We also observed enhanced migration of endothelial cells and
upregulation of MMP-9, which aids in the degradation of the extracellular matrix for
proper cellular migration. These in vitro results were supported by in vivo Matrigel
plug assays where SEMA5A showed enhanced microvessel density. Overall,
these data suggest that Sema5A-ECD is involved in physiological angiogenesis.
Taken together, SEMA5A regulates angiogenesis and cellular migration in PC
cells.
Diverse Signaling of SEMA5A:
SEMA5A is known to elicit contradicting outcomes in the case of cellular
migration by participating in both the migration and collapse of cellular growth
cones. On treatment with Sema5A, fibroblast cells showed disrupted focal
adhesions and inhibition of cellular migration (Artigiani et al., 2004). In 2010, Li and
Lee reported similar observations in the case of glioma cancer (Li and Lee, 2010).
However, SEMA5A stimulated invasiveness in pancreatic (Sadanandam et al.,
2012) and gastric cancer (Pan et al., 2013).
It is interesting to observe that the interaction of the same receptor-ligand
complex can lead to the activation of two different pathways in different cell types.
SEMA5A can induce invasive growth via Plexin B3 receptor signaling through the
Met receptor tyrosine kinase or the MEK/ERK pathway (Sadanandam et al., 2012).
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On the other hand, in the case of glioma cells, SEMA5A stimulates the Plexin B3
receptor to recruit Rho-GDIα which in turn blocks the guanine nucleotide exchange
for Rac1 and inhibits its migratory activity (Li et al., 2012b; Li and Lee, 2010) (Fig.
1.6). Two potential reasons for the activation of different pathways by the same
receptor-ligand complex can be the environmental context i.e. the ECM
components encountered by these molecules and the alternative interaction with
either the Sema or TSP domain. This bifunctionality of SEMA5A is also known to
exist during interaction with different proteoglycans like heparan sulfate and
chondroitin sulfate in the nervous system (Kantor et al., 2004).
Putative Receptors of SEMA5A:
A study using COS cells identified Plexin B3 as a high-affinity receptor for
Sema5A (Artigiani et al., 2004). In the same study, Sema5A was not found to
interact with Plexin B1 and Plexin B2. Also, both the Sema and TSP1 domains
were shown to interact with Plexin B3, and the oligomerization of the Sema domain
of Sema5A was found to be necessary for its functional response via plexin B3
receptor (Artigiani et al., 2004). Recently, it was shown that Sema5A mediated
retinal lamination is through the interaction with Plexin A1 and A3 receptors
(Matsuoka et al., 2011). Tamagnone et. al. has demonstrated the interaction of
Plexin A1 and A3 with NRP2 by co-precipitation experiments (Tamagnone et al.,
1999). Thus, there are many possible SEMA5A interaction partners, and it would
be interesting to investigate the receptor for SEMA5A in PC. The literature
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discussed in Section VI and VII is reviewed in detail by Purohit et. al (Purohit et al.,
2014).
Summary: PC is often considered a death sentence because the average
survival time of PC patients is only 5-8 months. The metastatic nature of the
disease necessitates further exploration and understanding of this process to
decrease the mortality rate of PC. Recent genomic characterization of PDAC and
accumulating evidence suggest that axon guidance cue molecules are important
for regulation of motility and metastasis (Casazza et al., 2007; Neufeld and
Kessler, 2008). In this dissertation, efforts are directed to understand the
pathological and functional relevance of one such molecule, SEMA5A in PC
progression and metastasis.
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VIII. Hypothesis and Specific Aims:
Significance: The high mortality in PC patients is primarily attributable to the
late detection and metastatic spread of the disease at the time of diagnosis.
Metastasis follows a predefined pattern of spread to specific organs, depending on
the origin of the primary tumor and interactions of cancer cells with the distant
organ-specific microenvironment. The goal of our work is to gain a better
understanding of the molecules and mechanisms mediating distant metastasis.
Application of this gained knowledge will pave the way to new diagnostics and
therapeutics for metastasis-specific treatment.
Recent literature suggests that axonal guidance cue molecules, in
particular, semaphorins, play a significant role in metastasis by affecting cellular
migration, angiogenesis, and survival in cancer. Our laboratory has identified one
semaphorin family member, SEMA5A, to be involved in organ-specific homing of
PC metastasis using in vivo peptide phage display library. Computational biology
strategies identified Plexin B3 as a putative binding partner of SEMA5A and
activation of Met tyrosine kinase by Plexin B3 is a known phenomenon. Previous
studies from our laboratory have demonstrated higher expression of SEMA5A in
PC cells established from distant metastasis in comparison with the primary tumor.
However, the precise role of SEMA5A in tumor growth and metastasis is not clear.
The primary goal of my research is to delineate the underlying molecular
mechanism of SEMA5A in PC progression with a major focus on its involvement
in metastasis.
37

Based on evidence from the literature, the central hypothesis of this project
is that SEMA5A through its interaction with Plexin B3 regulates PC metastasis by
enhancing cellular migration and aggressiveness in malignant cells. To test this
hypothesis pursued the following two specific aims:
Specific Aim 1: Ascertain the pathological significance of SEMA5A in PC
progression and metastasis.
Specific Aim 2: Evaluate the significance of the SEMA5A–Plexin B3
signaling axis in PC metastasis.
Impact: These studies will delineate the significance and pathological
relevance of differential expression of SEMA5A in PC progression and metastasis.
Furthermore, characterization of its cognate receptor Plexin B3 advances its
diverse signaling mechanisms. We expect that this study will positively influence
the efforts of developing anti-metastatic therapies as targeting cancer cells along
with molecules mediating various steps of the metastatic cascade are expected to
yield better results for cancer patients.
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Figure 1.1: The invasion-metastasis cascade.
A complex series of cellular processes, which are known as the invasionmetastasis cascade, leads to the formation of clinically detectable metastases.
In this metastatic progression, cancer cells invade the primary sites and enter
the nearby blood vessels by undergoing the process of intravasation. Cancer
cells translocate systemically by surviving in the circulation, followed by their
arrest at a distant organ site and undergoing extravasation to come out of the
blood vessels at a distant site. Cancer cells adapt themselves to survive and
thrive in the foreign microenvironments of distant tissues, which leads to the
formation of micrometastasis and eventually leads to metastatic colonization
and clinically detectable metastases. [Modified with permission from “Tumor
Metastasis: molecular insights evolving paradigms” (Valastyan and Weinberg,
2011)]
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Figure 1.2: Schematic representation of the process of EMT.
During the process of EMT, epithelial cells lose their contact with the
neighboring cells as well as the basal lamina. They also rearrange their
cytoskeleton and acquire spindle shape with the acquisition of mesenchymal
characteristics so that they can invade the neighboring tissue and migrate to
the metastatic site.
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Figure 1.3: The classes of the Semaphorin family.
Schematic representation of the classification of the Semaphorin family. The
basis of classification for Semaphorin family is the similarity of domain
architecture and the species which have the protein expression. All the classes
of this family have a characteristic seven-blade beta propeller structure called
the Sema domain in their N-terminus. Semaphorin members are either
transmembrane, membrane-anchored or secreted. Abbreviations, CRD:
Cystine rich domain, GPI: Glycophosphotidyl inositol.
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Figure 1.4: Structure of receptors Plexins and Neuropilins of Semaphorin.
Schematic representation of the domain architecture of Plexin and neuropilin
family members. Plexin family also shares the characteristic sema domain in
their N-terminus with other semaphorin family members. Plexins family
members can also be either cleaved to become secreted or membrane bound.
Abbreviations, CRD: Cystine rich domain, IPT: Immunoglobulin-like plexin
transcription factor, GAP: GTPase activating protein.The Classes of Plexin
family.
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Figure 1.5: Different modes of signaling of Semaphorin family members.
This schematic representation is demonstrating different modes of signaling for
secreted and transmembrane Semaphorins. Transmembrane Semaphorins
can interact in a cis (A) as well as a trans manner (B). In cis mode both the
interacting partners involved in eliciting a signal are present in the same cell. In
the trans mode, the interacting partners involved in eliciting a signal are present
on two different neighboring cells. Interestingly, transmembrane Semaphorins
can elicit both forward and reverse signaling. In the case of “forward” signaling,
Semaphorins act as a ligand whereas, in the case of “reverse” signaling,
Semaphorins act as a receptor and signal through their cytoplasmic domain.
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Figure 1.6: SEMA5A through Plexin B3 can trigger different intracellular
pathways.
This schematic representation is demonstrating that SEMA5A can promote or
inhibit the migration of cells based on the intracellular pathways triggered. By
acting through Plexin B3, SEMA5A enhances cellular invasion via mediating
interaction with MET receptor tyrosine kinase or by the activation of the
MEK/ERK pathway. However, SEMA5A (again acting through Plexin B3
receptor) inhibits cellular migration by recruitment of Rho-GDIα at its
intracellular domains, which in turn disrupts the Rac-1 activity.
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Chapter 2
Materials and Methods
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I. Human PC Specimens:
Tissue microarray (TMA) slides were obtained from two sources. TMA
obtained from the University of Nebraska Medical Center (UNMC) Rapid Autopsy
Program were constructed from paraffin blocks containing non-cancerous
pancreas, tumor cores, and metastases from several sites including liver,
diaphragm, and others. The study was approved by the Institutional Review Board
of the UNMC. Another TMA of PDAC (Accumax Array, A207III) containing thirtythree cases and eight unmatched normal pancreatic tissues in duplicate was a
generous gift from Petagene (Seoul, South Korea).
II. Mouse model of PC Disease Progression Specimens:
Primary tumor and metastases sections from the PDX-1-cre, LSL-KrasG12D
(KC) and of PDX-1-cre, LSL-Kras(G12D) p53

(lox/lox)

(KPC) mouse model at different

time points/ages (10-50 weeks) were obtained from our collaborator Dr. S. Batra,
Biochemistry and Molecular Biology, UNMC.
III. Cell Line Cultures and Transfections:
Human Cell Lines:
The PC cell line T3M-4 and CD18/HPAF cells were obtained as generous
gifts from Dr. Hollingworth’s and Dr. Batra’s laboratory respectively. The PC cell
lines L3.3 and L3.6pl were obtained as a generous gifts from Dr. I. J. Fidler in
University of Texas M.D. Anderson Cancer Center. These cell lines were
maintained in culture as an adherent monolayer in Dulbecco’s modified Eagle
medium (DMEM) (Hyclone Laboratories, Logan, UT) supplemented with 5% fetal
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bovine serum (Sigma-Aldrich, St. Louis, MO), 1% vitamin solution (Mediatech,
Herdon, VA), 1% L-glutamine and 0.02% gentamycin (Invitrogen, Carlsbad, CA).
PC cell line AsPC-1 was obtained from American Type Culture Collection
(Manassas, VA) and was cultured using Roswell Park Memorial Institute medium
(Sigma-Aldrich, St. Louis, MO) supplemented with 5% fetal bovine serum (FBS)
(Sigma-Aldrich), 1% L-glutamine (Mediatech), and 0.02% gentamycin (Invitrogen).
Cloning of SEMA5A/Plexin B3 shRNA Oligos:
SEMA5A-specific (5’-GCG GAT TTC CGC AGT TAA-3’), Plexin B3-specific
(5’- AGC AGA TGG TGG AGA GGT-3’) and scramble (control, 5’-GGC TAC GTC
CAG GAG CGC A-3’) oligonucleotides were selected using OligoEngine software
(OligoEngine Inc., Seattle, WA) and cloned downstream of the start codon in the
pSuper.neo vector, as instructed by the manufacturer (OligoEngine Inc.). The
oligonucleotide was annealed and cloned into the BglII and HindIII restriction site
using enzyme-digested pSuper.neo vector and the sequences were verified.
Vector pSuper.neo without insert was used as a negative control.
Transfection of PC Cells:
T3M-4 and CD18/HPAF cells were transfected with pSuper.neo/scrambled,
pSuper.neo/SEMA5A or pSuper.neo/Plexin B3 using LipofectAMINE Plus reagent
(Invitrogen, Carlsbad, CA) according to the protocol provided by the manufacturer.
Stably transfected cells were selected and maintained in neomycin sulfate (G418,
Mediatech)-containing media. Transfected T3M-4 and CD18/HPAF cells were
maintained in 1000 µg/mL and 600 µg/mL neomycin sulfate, respectively.
53

Similarly, shSEMA5A and control T3M-4 cells were transiently transfected with a
FLAG-tagged cDNA containing full-length mouse Sema5A cDNA in the BKCMV
vector (generous gift from Dr. Andreas W. Püschel, Westfälische WilhelmsUniversität Münster, Germany) or with the extracellular fraction of mouse Sema5A
conjugated to human IgG Fc expressed in the pcDNA3.1 vector (generous gift from
Dr. David Stretavan, University of California, San Fransisco, CA).
IV. Animal Models and Details of In vivo Studies:
Study Approval:
Mice were maintained under specific pathogen-free conditions. All
procedures performed were by institutional guidelines and approved by the
University of Nebraska Medical Center Institutional Animal Care and Use
Committee (IACUC).
Xenogenic Mouse Models:
Female athymic BALB/c nude mice (NCI-nu, 6-8 weeks old) were
purchased from the National Cancer Institute. For in vivo injection, cells were
harvested following trypsinization using a brief exposure with 0.25% trypsin in
0.02%EDTA (Invitrogen). Trypsinization was stopped with medium containing
serum, and then cells were washed twice with Hank’s balanced salt solution
(HBSS). Single cell suspensions of >95% viability (tested by trypan blue exclusion
assay) were used for injection.
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For the tumorigenic assay, mice were injected subcutaneously with 10 6
cells/0.05 mL of HBSS per animal into the lateral flank. Tumor growth was
monitored, and animals were euthanized when they were 10-weeks old. Tumors
were measured with calipers twice a week. Tumor volume was calculated by the
following formula: volume = W2 x L / 2, where W = short diameter and L = long
diameter. Tumor tissues were harvested and processed for further analysis.
For tumor growth and metastasis, tumor cells were injected orthotopically
into the pancreas. Mice were anesthetized, a small incision was created, and
pancreatic tumor cells (5 X 105 cells/0.05 mL HBSS) were injected into the anterior
lobe of the pancreas using a 1/2-cc U-100 insulin disposable syringe (EXEL
International Inc., Los Angeles, CA). A subcapsular intrapancreatic injection was
identified as successful by the appearance of a fluid bleb without leakage. To
prevent leakage, a cotton swab was held over the site of injection for 1 min. The
lesion was closed with two separate layers. The abdominal muscular layer was
closed using 4-0 or 5-0 vicryl or polydioxanone (PDS), and the outer skin layer was
closed with stainless steel wound clips. The animals tolerated the surgical
procedure well, and no anesthesia-related deaths occurred. Wound clips were
removed at approximately 10-14 days post-surgical procedure. Mice were
monitored for tumor growth. Details of the experimental model used for the
SEMA5A knockdown study and Plexin B3 knockdown study are described in the
schematics shown in Figure 2.1 and Figure 2.2, respectively. Animals
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weresacrificed when moribund. Primary tumors and metastases were resected
and processed for further analysis.
V. Gene Expression Analysis:
RNA Isolation:
Total cellular RNA was isolated from cells using TRIzol® reagent
(Invitrogen, Carlsbad, CA). Cells were washed three times with Phosphate Buffer
Saline (PBS) made in DEPC-treated water. Cells were scraped using a scraper
and pelleted at 7500 rpm for 5 min at 4°C. One mL of Trizol was used per well of
a 6-well plate. Cells lysed in Trizol were incubated at room temperature for 2-3
min. Chloroform (200 l) per 1 mL of TRIzol® reagent was added to the tube
containing the lysed cells, and the tube was shaken vigorously for 15 sec by hand.
The cells were centrifuged for 15 min at 12000 rpm at 4°C. After centrifugation; the
mixture separated into three phases. The lower phase was red in color, containing
phenol- chloroform followed by a thin interphase and an upper colorless aqueous
phase. RNA remained exclusively in the aqueous phase (approximately half of the
total volume). Following careful removal of the aqueous phase of the sample and
transferal of it to the fresh tube, 500 L of 100% isopropanol was addede to the
aqueous phase and the tube was incubated at room temperature for 10 min, then
centrifuged at 12,000 rpm for 10 min at 4°C. The supernatant was removed from
the tube, leaving only the invisible RNA pellet. The obtained pellet was washed
with 1 mL of 75% ethanol. The sample was vortexed briefly and then centrifuged
at 7500 rpm for 5 min at 4°C. The wash was discarded, and the RNA pellet was
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air dried for 5–10 min. Obtained RNA was resuspended in 20 L DEPC containing
water. RNA was quantified using absorbance at 260 nm, and the quality of the
RNA obtained was checked with a spectrophotometer using the 260/280 ratio.
Reverse Transcription:
The cDNA was synthesized using 2 µg of the obtained RNA for a 20 µL
reaction using iScript™ Reverse Transcription Supermix for RT-qPCR (BIO-RAD,
Hercules, CA, USA).
Quantitative Real-Time PCR (qRT-PCR):
qRT-PCR reactions were prepared using FastStart SYBR Green Master Mix
(Roche; Indianapolis IN, USA) and performed using BIO-RAD Connect machine.
BIO-RAD RFX Manager 3.1 software was used to run the analysis. Primer sets
used for the study are listed in Table 2.1. For real-time PCR, mean Ct values of
the target genes were normalized to mean Ct values of the endogenous control,
ribosomal

protein

large

13

A

(RPL13A)

or

Hypoxanthine-guanine

phosphoribosyltransferase(HPRT); [-∆Ct = Ct (RPL13A/HPRT) – Ct (target gene)].
The ratio of mRNA expression of target genes versus RPL13A was defined as 2(∆Ct).

Melting curve analysis was performed to check the specificity of the amplified

product. Amplified cDNA was resolved on EtBr containing 1% or 1.5% agarose
gels.
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VI. Protein analysis:
Protein Isolation, Quantification, and Immunoblotting:
Cells were washed three times using PBS and lysed using Membrane Lysis
Buffer (M-PER®, Pierce, Rockford, IL) containing protease inhibitors (complete
Mini, Roche Diagnostics, Mannheim, Germany). The cell lysate was incubated on
ice for 30 min followed by centrifugation at 10,000 rpm for 10 min at 4°C. The
supernatant was transferred into a fresh Eppendorf tube, and the protein
quantitation was performed using a BCA kit (Pierce™ BCA Protein Assay Kit
(Thermo Scientific, Rockford, IL, USA). Quantified protein (25 g) was denatured
using SDS Laemmli buffer (Laemmli, 1970). The denatured proteins were
separated on 10% SDS-PAGE at a constant voltage of 100V until the dye reached
at the end of the gel. The separated proteins were transferred to 0.45 m PVDF
membrane (Millipore, Billerica, MA) at constant voltage 100 V for 90 min. Next, the
membrane was blocked with 3% BSA in 0.1 % Tween containing Tris Buffer Saline
(TBST) for overnight at 4°C. The following day, the membrane was incubated with
a respective primary antibody (details in Table 2.2) for 2 hours at room
temperature or at 4°C overnight. The membrane was washed with TBST for 10
min for three times. After washing, the blots were incubated with secondary
horseradish peroxidase antibody (mouse (Sigma), 1:5000; rabbit (Thermo
Scientific), 1:5000) for an hour at room temperature. The membrane was washed
as described above. Finally, the blots were developed using the LuminataTM Forte
(Millipore) on Molecular Imager® Gel Doc™ XR System (BIO-RAD) using Image
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Lab version 5.2.1. The intensity of the bands obtained from immunoblotting was
measured using Image J software. Peaks were quantified for a protein of interest
and their respective loading control. Bands were normalized to the control cells
used in the study.
Enzyme-linked Immunosorbent Assay (ELISA):
Equal numbers (0.3 x 106) of T3M-4-control and T3M-4-shSEMA5Acells
were plated in 35 mm dishes in complete medium. After attachment of cells to the
plate, the medium was changed to serum-free DMEM. Supernatants of cultured
cells were collected at 48 hours. ELISA assay for TGF2 was performed using a
Duoset kit (R & D Systems, Minneapolis, MN, USA) according to the
manufacturer’s protocol. All the experiments were performed in duplicates.
Immunofluorescence:
Cells (1x105) were allowed to adhere overnight on 22x22 mm sized
coverslips (Fisherbrand ®, Pittsburgh, PA) in 6 well plates and cultured. After
washing twice with PBS, the cells were fixed using 4% paraformaldehyde in PBS
for 10 min. Next, cells were treated with 0.1% Triton-X for 10 min for
permeabilization, followed by incubation with the respective primary antibodies in
immunofluorescence solution (PBS with 5% BSA and 0.2% Saponin) for two hours
at room temperature. Secondary antibodies conjugated with either FITC (Jackson
Immunoresearch, West Grove, PA) or Cy3 (Jackson Immunoresearch) were
added for one hour at room temperature. Nuclei were counterstained with DAPI
(4, six diamidino-2-phenylindole) for 5 min at room temperature. Finally, slides
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were mounted with Vectashield® mounting medium (Vector Laboratories,
Burlingame, CA, USA). Immunofluorescence was detected using a Nikon
fluorescent or LSM 710 Zeiss confocal microscope.
Immunohistochemistry (IHC):
Fixed paraffin-embedded tissue samples on slides were deparaffinized in a
series of xylene and alcohol treatments (two times xylene, one time each in 100%,
95%, 80% and 70% alcohol) for 5 min each. Antigen retrieval was performed using
10 mM sodium citrate buffer (pH = 6.0). The slides were washed with PBS three
times for 5 min each and quenched for endogenous peroxidase activity by
incubating with 0.3% H2O2 in PBS for 30 min. Slides were again washed thoroughly
with PBS and blocked with antigen diluent reagent (BD Biosciences, Franklin
Lakes, NJ) for 30 min. Without further washing, the samples were incubated with
primary antibody (Table 2.2) in PBS overnight at 4°C. Biotinylated secondary
antibody (Vector Laboratories, Burlingame, CA) was applied for 30 min to 1 hour
after washing with PBS. The samples were then incubated with ABC reagent
(Vector Laboratories) for 30 min. Finally, DAB substrate (Vector Laboratories) was
added until a brown color developed and the slides were counterstained with
hematoxylin. Quantitation of cell number for a particular stain was determined by
counting at least five different random fields in the same section at 200x resolution
using a Nikon microscope.
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VII. In vitro Cell Based Assays:
In vitro Cell Proliferation Assay:
Cells (2x103 or 4X103) were seeded in 96-well plates and were allowed to
adhere. Cells were washed with HBSS and were incubated with medium alone or
medium containing different serum concentrations (1.25%, 2.5% or 5%) or medium
containing specified concentrations of the SEMA5A protein for 48 hours. Cell
viability was determined by MTT assay (3- (4, 5, dimethylthiazol-2-yl)-2, 5diphenylate-tetrazolium bromide, tetrazole) as previously describe (Li et al., 2001).
Cell Migration-Wound Healing Assay:
Cells (0.2x106) were plated per well in 12 well plate. The following day, the
cells had reached 90-95% confluency. A wound was generated using a 1 mL
pipette tip. Cells were washed with HBSS and incubated with either serum-free
medium or with serum-free medium with different concentrations of SEMA5A for
24 hours. Cells were photographed under an inverted microscope at a 40x
magnification at time T = 0 hours and T = 24 hours. The width of the wound was
measured using Image J software. Distance migrated was calculated by the
formula: Initial wound width (T = 0 hours) – Final wound width (T = 24 hours).
Chemotaxis Assay:
Chemotaxis assay was performed using Transwell chambers (Corning
Costar Corp., Cambridge, MA) with polycarbonate membrane containing 8.0 µm
pores. Cells (1 x 105) were plated onto Transwell chambers with serum-free media.
Media (serum-free) alone or media containing SEMA5A protein were kept in the
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bottom of 6-well plate, and the chambers were incubated at 37°C in 5% CO2 for
24 hours. After 24 hours, cells from the top of the Transwell chambers were
removed using a cotton swab (residual cells). The membrane was stained using
Hema 3 kit (Fisher Scientific Company L.L.C., Kalamazoo, MI) as per the
manufacturer’s instructions and cells were counted in five independent high-power
fields (200x), using a Nikon Eclipse E800 microscope.
Invasion Assay:
Invasion assay was performed using Transwell Corning® BioCoat™
Matrigel® Invasion Chambers with 8.0 μm PET Membrane in 6-well Plates. Cells
(1 x 105) were plated onto Transwell chambers with serum-free media and
incubated at 37°C in 5% CO2 for 24 hours. After 24 hours, cells from the top of the
Transwell chambers were removed using a cotton swab (residual cells). The
membrane was stained using a Hema 3 kit (Fisher Scientific Company L.L.C.,
Kalamazoo, MI) as per the manufacturer’s instructions and cells were counted in
five independent high-power fields (200x), using a Nikon Eclipse E800 Nikon
microscope.
Cell Scatter Assay:
Cells were seeded at a density of 2 x 102 cells per well in a 6-well plate in 3
mL of DMEM supplemented with 5% FBS and allowed them to grow as discrete
colonies at 37°C in a humidified atmosphere of 5% CO2 for 72 hours. When the
majority of colonies contained 20-30 cells, the medium was replaced by the DMEM
containing 5% FBS only or different concentrations of recombinant SEMA5A
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protein. After 16 hours of SEMA5A treatment, the medium was removed, and the
cells were washed with PBS. The cells were fixed with methanol at room
temperature for 10 min. After removal of methanol, the dish was allowed to air dry
and stained with Giemsa stain at room temperature for 15 min. The stain was
removed, and the dish was washed several times with distilled H2O and allowed to
air dry. The percentage of scattered colony was measured from the total number
of colonies counted. When half of the cells in the given colony had lost contact with
their neighbors and exhibited a fibroblast-like phenotype, it was judged as a
“scattered” colony.
Three-dimensional Colony Formation Assay:
Growth factor-reduced Matrigel was thawed on ice. Cells suspension with a
density of 1x104 cells per mL in serum-free media was used to dilute Matrigel in
1:1 ratio. Cell culture 96-well plate was kept on the ice.150 L of cells containing
Matrigel were plated per well and incubated at 37°C in a humidified atmosphere of
5% CO2 for half an hour. Culture media was added, and colonies were visualized
after 72 hours.
TOP-FLASH Assay:
Cells were plated into 12-well dishes. The following day, the cells were
transiently transfected with the TOP-flash or FOP-flash vector (0.5 µg/well) and a
Renilla Vector as a transfection control (0.1 µg/well), n=6 per cell line and vector.
Vectors were obtained from Promega (Madison, WI). Two days later, the cells were
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assayed for firefly/Renilla luciferase using the Dual-Glo reagent (Promega,
Madison, WI) as per the manufacturer’s instruction.
VIII. Quantification and Analysis
IHC Scoring and Analysis:
The scoring of IHC was performed in accordance with following criteria:
percentage of positive cells on the slides was numbered as follows: 0 (negative),
0.1 (1%–10% of cells positive), 0.2 (11%–20% of cells positive), and 0.3 (20%30% of cells positive) and more. Furthermore, the intensity was designated as
weak (1 point), moderate (2 points), strong (3 points) or very strong (4). The IHC
composite score was calculated by multiplying the extent of positive cells with
intensity. Two independent observers examined each slide, and their observations
were positively correlated with each other. Average scores were used for analysis
and if the two observers significantly differed in their scoring, a third observer
examined the slide.
Quantification of Lamellipodium and Filopodium:
For quantification of lamellipodium and filopodium, the actin cytoskeleton
was stained as described in the section of immunofluorescence using Texas Red
Phalloidin (Molecular Probes) for 20 min. We quantified the number of cells,
lamellipodia, and filopodia with a free edge in 5 different random fields in the same
coverslip at 630x resolution using a LSM 710 Zeiss Confocal Microscope. We
counted the number of Lamellipodia and Filopodia per cell.
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Statistical Analysis:
Statistical analysis was conducted using GraphPad Prism software
(GraphPad Software, Inc., La Jolla, CA). The significance was determined by
Student’s t-test or nonparametric Mann-Whitney U-test. Comparisons between
different groups were evaluated using parametric or Kruskal-Wallis nonparametric
Analysis of Variance or followed by Bonferroni adjustment for multiple
comparisons. For all statistical tests, a p-value of ≤ 0.05 was considered
significant.
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Table 2.1 List of Human Primers Used for the Study:

1
2
3

Gene

Temper
ature

Size

Orientation

Primer Sequence

E-cadherin

58°C

314

Forward
Reverse

AGTGCCAACTGGACCATTCA
TCTTTGACCACCGCTCTCCT

58°C

217

Forward
Reverse

TCAGGCTGTGGACATAGAAACC
GCTGTAAACGACTCTGGCACT

58°C

159

Forward
Reverse

GTCCGCAGTCTTACGAGGAG
CCAGCTTGAGGGTCTGAATC

N-Cadherin

TWIST

4

SNAIL

58°C

207

Forward
Reverse

TTTACCTTCCAGCAGCCCTA
CCCACTGTCCTCATCTGACA

5

RPL13A

58°C

126

Forward
Reverse

CCTGGAGGAGAAGAGGAAAGAGA
TTGAGGACCTCTGTGTATTTGTCAA

6

HPRT

58°C

144

Forward
Reverse

AGGGTGTTTATTCCTCATGGAC
GTAATCCAGCAGGTCAGCAAAG
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Table 2.1 List of Antibodies Used for the Study:

Antibody with Species
Reactivity

Supplier and
Catalogue
Number

SEMA5A

Invitrogen

(Human, Mouse)

(PA5-12278)

E-cadherin

Gift from Dr.
Keith Johnson

1

2
(Human, Mouse)

N-cadherin

(Hybridoma
Supernatant)

-catenin

(Hybridoma
Supernatant)

PCRP-SNAI3
5
(Human)

TWIST
6
(Human, Mouse)

PCNA
7

(Human, Mouse)

IF
(Dilution)

Rabbit

1:1000

Mouse

1:100

1:5

Mouse

1:100

1:5

Mouse

1:200

1:10

Mouse

1:100

Rabbit

1:200

IHC
(Dilution)

Gift from Dr.
Keith Johnson

4
(Human, Mouse)

WB
(dilution)

Gift from Dr.
Keith Johnson

3
(Human, Mouse)

Host
Species

(Hybridoma
Supernatant)
Developmental
Studies
Hybridoma
Bank

Santa Cruz
Biotechnology
15393

Santa Cruz
Biotechnology

1:100

Mouse

sc-56

SEMA5A
8
(Human, Mouse)

Singh-labpurified

Rabbit

(1mg/mL)

67

1:25

1:50

9

Texas Red Phalloidin

Molecular
Probes

10

CD31

Abcam
(28364)

Rabbit

11

Plexin B3
(Human, Mouse, Rat)

Santa Cruz
Biotechnology
(sc-67144)

Rabbit

1:200

12

Met
(Human, Mouse, Rat)

Santa Cruz
Biotechnology
(sc-8307)

Rabbit

1:200

1:50

1:50

13

GAPDH
(Human, Mouse)

Santa Cruz
Biotechnology
(sc-59541)

Mouse

1:2000

14

-Actin
(Human, Mouse)

Sigma
(A2066)

Rabbit

1:5000

p-MET
(Tyr1234/1235)
(Human, Mouse, Rat)

Cell Signaling
#3077

Rabbit

1:1000

16

PI3K
(Human, Mouse)

Abcam
86714

Mouse

1:1000

17

p-PI3K
(p85(Tyr458/p55(Tyr199)
(Human, Mouse)

Cell Signaling
#4228

Rabbit

1:1000

15

68

1:50

18

AKT
(Human, Mouse)

BD
Transduction
Laboratories TM
610861

Mouse

1:1000

19

p-AKT
(Ser473)
(Human, Mouse)

Cell Signaling
#9271

Rabbit

1:1000

Cell Signaling
#12456

Rabbit

1:1000

Cell Signaling
#9336

Rabbit

1:1000

20

21

GSK3
(Human, Mouse, Rat)

p-GSK3
(Ser 9)
(Human, Mouse)

69

70

Figure 2.1: The experimental model used for evaluation of the metastatic
potential of T3M-4 Control and T3M-4-shSEMA5A cells.
This schematic diagram is representing the experimental strategy used for
tumor implantation and end-point analysis of the growth of T3M-4 Control and
T3M-4-shSEMA5A cells in athymic nude mice.
.
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Figure 2.2: The experimental model used for evaluation of the metastatic
potential of CD18/HPAF-Control and CD18/HPAF-shPlexin B3 cells.
This schematic diagram is representing experimental strategy used for tumor
implantation and end-point analysis of CD18/HPAF-Control and CD18/HPAFshPlexin B3 cells in athymic nude mice.
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Chapter 3
Differential Expression of SEMA5A in PC Progression and Metastasis
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I. Abstract:
Identified as a cell adhesion molecule involved in organ-specific metastasis,
SEMA5A has differential cell surface expression between normal and cancer cells
and represents an attractive target for therapeutic intervention in PC. In this study,
we delineated the pathological expression of SEMA5A during PC progression and
metastasis. We utilized human Tissue Microarray (TMA) and took advantage of
three different mouse models of PC disease progression, including exocrine as
well as neuroendocrine tumors. KC and KPC mice were used for studying
SEMA5A expression in PDAC, and the RIP1-Tag2 (RT2) model of islet-cell
carcinoma was used for PanNET. Using IHC, SEMA5A expression was analyzed
on human and mouse tissue sections qualitatively. Our results demonstrate
highest SEMA5A expression in liver metastases in human, followed by primary
pancreatic tumor with least/no SEMA5A expression in the normal pancreas.
SEMA5A expression was localized on the membrane of tumor cells with no
staining for surrounding stroma. Likewise, in the KC mouse model, SEMA5A
expression was low in the normal pancreas but increased with disease progression
in tumor tissues. We also observed positive SEMA5A expression at different
metastatic sites in the KPC mouse model. Similar to PDAC, in endocrine tumors,
we observed higher SEMA5A expression in liver metastases in comparison with
normal and primary tumors in the RT2 PanNET mouse model and human PanNET
patient samples. Overall, we conclude that SEMA5A expression is upregulated
during PC initiation and this expression is furthermore elevated at metastatic sites,
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especially liver, in both exocrine and endocrine tumors. Therefore, SEMA5A
represents a potential molecule for targeting metastasis and has stage-specific
expression in the primary tumor.
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II. Introduction:
Semaphorins are well known for their role as guidance and migration cues
for a cell to reach the target site during the embryonic development of nervous
system and cardiovascular patterning (Eichmann et al., 2005; Epstein et al., 2015;
Tamagnone and Comoglio, 2000). Recent literature suggests aberrant expression
of axonal guidance cue molecules in cancer, and their dysregulated signaling plays
a significant role in cancer angiogenesis and metastasis (Gu and Giraudo, 2013;
Muratori and Tamagnone, 2012; Neufeld and Kessler, 2008; Neufeld et al., 2016;
Neufeld et al., 2012; Rizzolio and Tamagnone, 2007). Our lab identified one such
molecule (SEMA5A) to be involved in organ-specific homing during PC
(Sadanandam et al., 2007; Sadanandam et al., 2010b). Understanding the pattern
of expression of SEMA5A in primary tumors and metastasis with relevance to PC
disease progression and stages can increase the candidacy of this molecule for
the development of novel diagnostic and targeted therapies in future.
One of the parameters to be effective in the clinic is the evaluation of a
target in different models of PC malignancy (Olive and Tuveson, 2006). In the past
few years, many mouse models of PC have been developed that provide
information about the development and genetic causes of PC (Hruban et al., 2006).
The popular models are based on murine Kras gene mutation in pancreatic
progenitor cells, such as conditional activated Kras in KC (Hingorani et al., 2003;
Tuveson et al., 2004) and KPC (Hingorani et al., 2005; Olive et al., 2004). These
bear a striking similarity to the human PDAC condition (Olive and Tuveson, 2006)
77

and recapitulate the histopathologic condition of metastasis to relevant sites. Both
KC and KPC models enable the evaluation of cellular pattern and identification of
the time point of expression of a molecule of interest during PDAC disease
development.
Mouse models different from the one described above are utilized to study
the endocrine type of PC. The RT2 model is the most popular one for studying
PanNET (Tuveson and Hanahan, 2011). In this model,-cell-specific expression
of the SV40 T-antigen leads to islet-cell carcinomas (Hanahan, 1985). The SV40
T-antigen under the regulation of the rat insulin promoter induces tumorigenesis in
pancreatic islet cells by inactivation of the p53 and retinoblastoma tumor
suppressor pathways (Hunter et al., 2013).
Currently, SEMA5A expression has not been evaluated during PC disease
progression and in metastasis. Thus, to understand the probable pathological roles
of SEMA5A in PC, we first evaluated the expression pattern of SEMA5A in human
PC primary tumor and metastasis tissue specimens. Furthermore, using
pancreatic tissues derived from the KC and KPC mouse models, we analyzed the
pattern of SEMA5A expression during the development and progression of PDAC.
Additionally, we identified the SEMA5A expression pattern in PanNET
progression, by utilizing the RT2 mouse model. Understanding the pattern of
expression of SEMA5A in primary tumors and metastasis with relevance to PC
disease progression and stages will furthermore elucidate whether there is a
possibility of utilization of this molecule as a target for the development of
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biomarkers or targeted therapies in future. Our data demonstrate that SEMA5A
expression is increased during PC initiation and is dependent on the stage of the
disease. Furthermore, SEMA5A expression is also observed at different metastatic
sites and represent a potential molecular target.
III. Results:
SEMA5A Expression Depends on the Differentiation Status of PC:
We performed SEMA5A IHC analysis on a TMA containing 33 cases of
human patients with PC and four unmatched normal pancreatic tissues in
duplicate. SEMA5A expression was mainly observed in PC tumors whereas
normal tissue either showed low or no expression, and the expression was
localized on the membrane of tumor cells with no staining for surrounding stroma
(Fig. 3.1A). We also analyzed the correlation of SEMA5A expression with
differentiation status of the tumor. SEMA5A expression was significantly higher (p
< 0.05) for well differentiated (n = 4) and moderately differentiated (n = 15) tumors
in comparison with poorly/undifferentiated (n = 8) tumors as well as normal
pancreatic tumors (n = 4) (Fig. 3.1A, 1B). Furthermore, analysis of SEMA5A
expression within different stages of PC revealed a significant difference (p < 0.05)
in SEMA5A expression between normal pancreatic tissues and different stages of
PC (Fig. 3.1C). We also observed lower SEMA5A expression for advanced stages
like Stage IIB (n = 10) and Stage IV (n = 12) than initial stages like Stage IB (n =
2) and IIA (n = 6), but this difference in SEMA5A expression was not significant
among stages (Fig. 3.1C).
79

SEMA5A Gene Amplification Occurs in PC Cases:
Using The Cancer Genome Atlas (TCGA) Database, we analyzed copy
number variation of SEMA5A in pancreatic adenocarcinoma cases. We found the
gain of SEMA5A gene in 35 out of 49 pancreatic adenocarcinomas (Fig. 3.1D).
The gain of SEMA5A gene ranged between the value of 2 to 3 of copy number in
a diploid cell.
SEMA5A Expression is Higher at Metastatic Sites in Comparison with the Primary
Tumor:
With an interest to evaluate SEMA5A expression between primary cancer
and different metastatic sites, we utilized a TMA with 21 cases of PC patients with
primary tumor and either one, two or three metastatic sites like liver, diaphragm,
and bowel. IHC scoring of SEMA5A was highest for a liver metastatic site (n =16)
with a significant difference between normal (n = 3) (p < 0.001) /primary cancer (n
= 17) (p < 0.05) and liver metastasis (Fig. 3.2A, 2B). There was no significant
difference in SEMA5A expression at diaphragm metastatic site (n = 14) and the
primary tumor of human PC metastasis specimens. We also observed non-specific
background staining of SEMA5A for normal liver cells.
We also analyzed SEMA5A expression in metastatic variants derived from
fast-growing (FG) COLO 357 cells, as described by Burns et. al in their in vivo
selection study using orthotopic implantation in nude mice (Bruns et al., 1999). We
observed higher SEMA5A expression in highly metastatic L3.6pl cells than the low
metastatic potential L3.3 cells (Fig. 3.2C).
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Sema5A Expression is Higher in the Cancerous Lesions of KC Mice than in the
Normal Pancreas:
To evaluate Sema5A expression during PC disease progression, KC mice
pancreatic tissues derived from mice sacrificed at different time points (10, 20, 30
and 50 weeks) were used to generate a progression model. We observed no
expression of Sema5A in the normal pancreas, derived from the control PDX-cre
mice. However, tumors in KC mice beginning at 10 weeks of age were positive for
Sema5A expression (Fig. 3.3). This expression was further intensified in the
tumors of mice at 20, 30 and 50 weeks age. The pancreas of a 50-week aged
mouse represents fully developed PDAC. Similarly to SEMA5A expression in
human pancreatic tissues, localization of Sema5A expression in mice was on the
membrane of tumor cells with no staining for surrounding stroma. We observed
non-specific background staining in acinar ducts of the pancreas.
Metastatic Sites of KPC Mice are Positive for Sema5A Expression:
With an objective to evaluate Sema5A expression at metastatic sites, we
utilized the KPC mice model to derive metastatic site tissues from the liver, lymph
node, peritoneum, and diaphragm.of mice sacrificed at 50-week time point. We
observed that Sema5A expression is positive for all the cancer cells established at
the metastatic site except lymph nodes (Fig. 3.4).
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Sema5A Expression is High in Angiogenic Islets and Metastasis-like-Primary
(MLP) Tumors in PanNET:
We investigated the Sema5A mRNA expression profiles from the
progressive stages of the disease in RT2 mice. Sadanandam et. al. in their study
of cross-species analysis of PanNET provides a description of parameters for
hierarchical clustering and resulting stage-classified groups (Sadanandam et al.,
2015). The stages of disease progression described in this paper are normal,
hyperplastic, and angiogenic islets. Furthermore, classification of primary tumor
samples by their similarities with the metastases resulted in the formation of two
distinct groups called metastasis-like primary (MLP) and well-differentiated
islet/insulinoma tumors (ITs). As the name suggests, gene expression of MLP was
similar to the gene expression at metastatic sites in the RT2 model. This dataset
included pools of normal (n = 3), hyperplastic/dysplastic (n = 3), and angiogenic (n
= 3) islets, as well as individual tumors (n = 10) and liver macrometastases (Mets;
n = 3). In this mRNA evaluation, we found upregulation of SEMA5A expression in
liver metastasis in comparison with normal islets (Fig. 3.5A), followed by MLP and
angiogenic islets. On the other hand, hyperplastic/dysplastic islets and well
differentiated IT showed downregulation of SEMA5A expression in comparison
with normal islets.
Next, SEMA5A expression was evaluated in human mRNA transcriptomes
of PanNET patients using NMF consensus clustering analysis as described by
Sadanandam et al in a cross-species analysis of PanNET (Sadanandam et al.,
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2015). This mRNA transcriptome had core clinical gene expression information for
86 patients classified as nonfunctional PanNETs, insulinomas, and normal
pancreatic islet samples (Missiaglia et al., 2010). This dataset included four normal
islets, 75 primary tumors positive or negative for metastasis, and seven samples
of either liver or lymph node metastases. Highest SEMA5A mRNA expression was
found in liver metastasis in comparison with normal islets (Fig. 3.5B, 5C) followed
by primary tumors positive for metastasis. In contrary, SEMA5A mRNA expression
was down-regulated in lymph node metastasis, and we observed no change of
SEMA5A expression in patients negative for metastasis.
IV. Discussion:
There is an urgent need to identify new targets in PC that can bring down
the rate of metastasis-driven mortality. An ideal target for such a case will be a
molecule that can restrict the escape of a cancer cell by targeting metastatic
cascade. Guidance cue molecules represent an attractive class for such a
scenario. In the family of guidance cue ligands, Semaphorins represent the largest
and the most well-studied member and are well-known players in angiogenesis
and cellular migration processes in cancer. Our group became interested in the
SEMA5A molecule, which belongs to the class 5 of Semaphorin family, due to the
organ-specific homing property of the seven amino acid peptide NAFTPDY of this
molecule (Sadanandam et al., 2007). In this earlier study (Sadanandam et al.,
2007) performed for the identification of cell adhesion molecules critical for
metastasis, SEMA5A emerged as an important candidate for targeting PC
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metastasis. In this present study, we furthermore tested the prospects of SEMA5A
as a target by analyzing the pattern of SEMA5A expression in both human and
murine primary pancreatic tumor tissues as well as metastases, and normal
pancreas (Fig. 3.6).
With this objective, we utilized human PC TMA of primary cancer and
metastasis as well as the human PanNET patient database. We also took
advantage of KC and KPC mouse models for studying SEMA5A expression in
PDAC and the RT2 model of islet-cell carcinoma for PanNET. The KC and KPC
models are generated by crossing mice with a conditional activated Kras allele
(LSL-KrasG12D) to either of Pdx-Cre or p48Cre recombinase in pancreatic lineages
(Hingorani et al., 2003; Tuveson et al., 2004). KC mice successfully develop PanIN
but develop PDAC tumors only at an advanced age. This condition suggests Kras
alone cannot drive tumor formation and additional events are necessary before
tumor formation could proceed. To overcome this problem, animals expressing
Pdx-Cre with multiple conditional mutations were generated such as both Kras and
Trp53 (Hingorani et al., 2005; Olive et al., 2004). Thus, KPC mice with Kras and
Trp53 mutation develop PanIN lesions at an early age, which leads to the
occurrence of metastasis to relevant sites. Likewise, the RT2 mouse model of islet
cell carcinoma has been instrumental in studying PanNET progression and has
been utilized for prediction of clinical efficacy of new therapeutics.
Our results demonstrate an increased expression of SEMA5A in the
metastasis and primary tumor burden of human and mice PC tissue. The normal
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pancreas was either negative or showed low expression of SEMA5A. The
localization of SEMA5A was on the membrane of tumor cells with no staining for
surrounding stroma. The increase of SEMA5A expression in primary tumor also
goes by our observation of gain of copy number in SEMA5A in pancreatic
adenocarcinoma patients. Likewise, a study of samples from gastric carcinoma
patients illustrated elevated expression levels of both SEMA5A and its receptor
plexin-B3 in primary gastric carcinoma and lymph node metastasis in comparison
to the non-neoplastic tissue (Pan et al., 2009). On the other hand, although not
significant, we found a decrease of SEMA5A expression in an advanced stage of
PC progression
Next, we for the first time have identified the expression of Sema5A in the
disease progression model of KC mice with tumor sections obtained at different
week/time points (10-50 week). We identified the qualitative increase of Sema5A
expression in the pre-cancerous lesions of20-week old KC mice which became
further elevated with increasing time points. This observation does not go in hand
with what we have seen for human PC patients. The possible reasons for these
contrary results could be limited sample size of early staged PC patients, as most
of the diagnosis occurs at an advanced stage for these patients. Another reason
could be that our observations in the KC mouse progression model are at a
qualitative level. Lastly, in these mouse models, we are examining Sema5A
expression in the presence of Kras as a driver mutation, which may not reflect the
entire representation of patient samples present in the TMA.
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We also compared Sema5A expression at different metastatic sites like
liver, mesenchymal lymph node, peritoneum, and diaphragm in KPC mice, and we
observed positive Sema5A expression for different metastases except lymph
nodes. In endocrine tumors as well, we observed the similar pattern of highest
SEMA5A expression at liver metastasis followed by primary tumor burden with no
expression in normal pancreas. In contrary to SEMA5A analysis in human patient
TMA, which revealed higher SEMA5A expression in differentiated tumors than
poorly/undifferentiated tumors, in the RT2 model we observed downregulation of
SEMA5A expression in well-differentiated IT tumors, and higher SEMA5A
expression in poorly differentiated MLP. Li et al. in 2010 have published similar
findings on SEMA5A in glioblastoma in regards with differentiation in human
patient samples, demonstrating that the treatment of glioblastoma cell lines with
SEMA5A impaired cellular motility and promoted differentiation (Li et al., 2012b; Li
and Lee, 2010). Interestingly, lymph node metastases of human PanNET patients
showed downregulation of SEMA5A expression. Similarly, in KPC mice
metastasis, we did not observe any variation in Sema5A expression in different
metastatic sites except lymph nodes. Lymph node metastasis may represent
cancer cells in transition that do not upregulate cell adhesion molecules such as
SEMA5A. Lastly, though PDAC and PanNET represent malignancy of pancreas,
they each have different pathophysiology.
In summary, our data demonstrate that expression of SEMA5A in PC may
be of predictive value for the occurrence and progression of PC. Thus, SEMA5A
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may represent a potential target for the diagnosis and treatment of pancreatic
tumors in the future.

87

88

Figure 3.1: Increased SEMA5A expression is observed in human PC
primary tumor in comparison with the normal pancreas.
(A) Representative images showing SEMA5A expression in normal pancreas,
primary well differentiated and poorly differentiated PC in human patients.
Images are taken at 200x using a Nikon Eclipse E800 microscope. (B, C) Bar
graph showing SEMA5A immunohistochemistry (IHC) score between tumors at
different cellular differentiation status and normal tissues and different stages
of tumors and normal tissues. Shown with symbol “a” (a) are the significant
statistical differences (p ≤ 0.05) between various tumors and the normal
controls. Similarly, the symbol “b” (b) represent significant statistical differences
(p ≤ 0.05) between various tumors and poorly/undifferentiated tumors.
SEMA5A expression is higher in different stages in comparison with the normal
tissues and the higher SEMA5A expression is seen in well-differentiated tumors
in comparison with normal and poorly/undifferentiated tumors. SEMA5A
expression in tumor tissue (n = 33 in duplicates) and normal pancreas (n = 4 in
duplicates) in TMA was examined using IHC. The values are mean IHC
composite score ± Standard Error of Mean (SEM). The significance of the data
was determined by the non parametric Mann-Whitney U-test (two-tailed). A
value of p < 0.05 was deemed significant. (D) Pancreatic Adenocarcinoma
cases show the gain of SEMA5A gene copy number as observed using The
Cancer Genome Atlas (TCGA) Database. The X-axis represents log 2 value of
copy number, and the Y-axis represents individual pancreatic adenocarcinoma
(n = 49) cases. The gain of SEMA5A gene ranged between the value of 2 to 3
in copy number calculated by the formula 2*(log20-log20.5) in a diploid cell.
However, aberrant gene expressions have a gain of copy number greater than
3.
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Figure 3.2: Increased SEMA5A expression is observed in human PC
metastatic sites in comparison with the normal pancreas and primary
pancreatic tumor.
(A) Representative images are showing SEMA5A expression in normal
pancreas, primary PC and metastatic sites like liver and diaphragm in human
patients. Images were taken at 200x using a Nikon Eclipse E800 microscope.
(B) The graph shows higher SEMA5A IHC Score at metastatic sites in
comparison with the primary tumor, evaluated using TMA with 21 cases of PC
patients. The values are mean IHC composite score ± SEM. We found the
highest IHC scoring of SEMA5A for liver metastatic site (n = 16) with a
significant (p ≤ 0.001) difference between normal (n = 3)/primary cancer (n =
17). The significance of the data was determined using one-way ANOVA with
(*p ≤ 0.05, **p ≤ 0.01, ***p ≤ 0.001,

ns

p > 0.05). Black bars represent a

comparison between groups with respect to normal, blue bars represent a
comparison between different groups with respect to primary pancreatic tumor
and red bars represent comparison between groups with respect to the liver.
(C) Western blot analysis is showing higher SEMA5A expression in L3.6pl (high
metastatic potential) in comparison with L3.3 (low metastatic potential) cell lines
using GAPDH as a loading control. Quantification of the SEMA5A by their
intensity of the bands with respect to their loading control GAPDH was
performed by Image J software. Bands were normalized on the L3.3 cells.
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Figure 3.3: Sema5A expression progressively increases in the developing
cancerous lesions of KC mice.
Representative images of Sema5A immunohistochemistry performed on the
progression model derived from tumors of KC mice (n = 5) at different ages (10
weeks, 20 weeks, 30 weeks and 50 weeks) demonstrating progressively
increasing qualitative Sema5A expression. The normal pancreas of 50-week
Pdx1-cre mice is negative for Sema5A expression. The images were taken at
200x magnification using a Nikon Eclipse E800 microscope.
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Figure 3.4: Metastatic sites of KPC mice are positive for the Sema5A
expression.
Representative images of Sema5A immunohistochemistry performed on
metastatic sites (mesenchymal lymph node (n = 1), liver (n = 5), diaphragm (n
= 1), and peritoneum (n = 2)) of KPC mice, demonstrating that metastatic sites
are positive for the expression of Sema5A except lymph node. The images
were taken at 200x magnification using a Nikon Eclipse E800 microscope. “N”
represents normal tissue while “M” represents metastasis.
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Figure 3.5: SEMA5A expression is higher at metastasis in comparison
with normal islets in PanNET cases.
(A) Expression of Sema5A as median-centered fold change with respect to
normal islets (N; n = 3) in different stages (hyperplastic/dysplastic (H; n = 3)
islets and angiogenic (A; n = 3) islets), tumor subtypes (n = 10; classified into
Insulinoma/Islet Tumors (IT) and Metastasis Like Primary (MLP) Tumors) and
liver metastases (Mets; n = 3) of RT2 mouse model of PanNET. Angiogenic
islets, MLP tumors, and liver metastases show upregulation of Sema5A with
respect to normal islets. (B) Expression of SEMA5A as median-centered fold
change with respect to normal islets in primary tumor with (Yes) or without (No)
metastasis and liver (Liver) and lymph node (Lymph Node) metastases from
human PanNETs. This dataset included four normal islets, 75 primary tumors
positive or negative for metastasis and seven samples of either liver or lymph
node metastases. The significance of the data is determined using Student ttest (*p ≤ 0.05, **p ≤ 0.01, ***p ≤ 0.001, nsp > 0.05). (C) Representative images
of SEMA5A immunohistochemistry performed on pancreas and liver of a
patient suffering from PanNET. The images were taken at 200x magnification
using a Nikon Eclipse E800 microscope.
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Figure 3.6: Expression levels of SEMA5A in PC.
Schematic showing representation of SEMA5A expression in normal pancreas,
primary tumor, and metastatic sites, analyzed utilizing different PC mouse
models and human patient samples in TMA. Schematic representation
suggests an increase in SEMA5A expression in PC with low or no expression
in normal pancreas. Furthermore, SEMA5A expression is also present in PC
metastatic sites like liver, spleen, and others. Especially, for pancreatic
neuroendocrine cases, metastatic sites show furthermore upregulation of
SEMA5A expression in comparison with the primary tumor.
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Chapter 4
SEMA5A Regulates Cellular Motility in PC Through the Plexin B3 Receptor

100

I. Abstract:
Previous reports from our laboratory provide evidence that SEMA5A
enhances PC metastasis. Based on the results obtained from our previous studies,
we hypothesized that SEMA5A induces cellular migration and thereby enhances
PC metastasis through its interaction with receptor Plexin B3 in malignant cells. To
test this hypothesis, we stably down-regulated the expression of Plexin B3 in cell
lines T3M-4 and CD18/HPAF and evaluated migratory response using wound
scratch assay, scattering assay, chemotaxis, and staining the actin cytoskeleton.
Activation of Met receptor in the presence of SEMA5A was examined using
Western blots. Treatment of Control- and Plexin B3- knockdown T3M-4/
CD18/HPAF cells with SEMA5A resulted in the higher migration in the Control cells
in comparison with shPlexin B3 cells. Another piece of supporting evidence
indicating increased migratory response came from the treatment of Control cells
seeded at low density with SEMA5A that demonstrated an increased formation of
membrane ruffles, showing dismantling of stress fibers in cells treated with
SEMA5A compared with the untreated cells. Similarly, Control colonies showed an
increased scattering response under the treatment of SEMA5A, but the similar
effect of SEMA5A treatment was absent in the shPlexin B3 colonies. We observed
lower chemotaxis towards SEMA5A in Plexin B3 knockdown cells. Lastly,
SEMA5A treatment also led to phosphorylation of Met at tyrosine 1234/1235 in
control cells, which represent activation of this receptor. In summary, our data
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demonstrate that SEMA5A can elicit migratory response and activation of Met
through the Plexin B3 receptor.
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II. Introduction:
A growing body of evidence now supports the roles of various semaphorins
in oncogenesis via their involvement in pathological processes such as
angiogenesis and cellular migration during metastasis (Neufeld and Kessler, 2008;
Neufeld et al., 2016; Neufeld et al., 2012; Rehman and Tamagnone, 2013; Rizzolio
and Tamagnone, 2007; Sakurai et al., 2012; Tamagnone and Comoglio, 2004;
Trusolino and Comoglio, 2002). Semaphorins are well recognized as major
regulators of cellular migration and guidance to reach their respective targets. The
gain of migration ability with the loss of cellular adhesion is a key event in the
process of metastasis. Metastasis represents the reason for 90% of cancer-related
death (Das and Batra, 2015; Rahib et al., 2014; Siegel et al., 2017). Metastatic
nature of PC is majorly responsible for the significantly worse prognosis of PC
patients (Oberstein and Olive, 2013). For decreasing mortality rate in PC, further
exploration of the molecular mechanism(s) that lead to metastatic dissemination is
warranted (Fidler and Kripke, 2015; Steeg, 2016).
The importance of these axonal guidance cue ligands gains supports from
a recent study demonstrating aberration in axonal guidance cue pathways in the
PC genome (Biankin et al., 2012). Semaphorins and their receptor Plexins
represent the largest and the well-characterized class of the axon guidance cue
family (Tamagnone and Comoglio, 2000). Semaphorins are either secreted or
membrane-bound and have a conserved “Sema” domain towards their N-terminus.
Subclass 5 of this family comprises transmembrane semaphorins, and in addition
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to the Sema domain, they contain a unique extracellular domain containing seven
thrombospondin type 1 repeats. Several studies have demonstrated the
expression and role of subclass 5 member SEMA5A in various malignancies
including glioma, lung, prostate, melanoma and gastric (Balakrishnan et al., 2009;
Li et al., 2012a; Li and Lee, 2010; Lu et al., 2010; Pan et al., 2010; Pan et al., 2013;
Pan et al., 2009). Previous reports from our laboratory provide evidence that
SEMA5A enhances PC metastasis (Sadanandam et al., 2012; Sadanandam et al.,
2007; Sadanandam et al., 2010b). Our group identified SEMA5A as a putative cell
adhesion molecule involved in organ-specific homing of PC cells (Sadanandam et
al., 2007). We also demonstrated that SEMA5A overexpression in a PC cell line
endowed enhanced metastatic potential when the cells were implanted in an
orthotopic nude mouse model (Sadanandam et al., 2010b). Interestingly,
overexpression of the secreted form of SEMA5A showed further enhanced micro
metastases to the liver, with a lower primary tumor burden, when orthotopically
implanted in the nude mice (Sadanandam et al., 2012).
Furthermore, previous studies report Plexin B3 as a SEMA5A interacting
partner in non-pancreatic tissue (Artigiani et al., 2004; Sadanandam et al., 2008).
A study of samples from gastric carcinoma patients demonstrated the pathological
relevance of this interaction, showing the elevated expression of both SEMA5A
and Plexin B3 in primary gastric carcinoma and lymph node metastasis in
comparison to the non-neoplastic tissue (Pan et al., 2010; Pan et al., 2009).
Various PC cell lines also document the co-expression of SEMA5A and Plexin B3
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(Sadanandam et al., 2008). Like SEMA5A, Plexin B3 and Met also shares the
structural sema domain, and Met has been implied to form receptor complexes
with Plexin B3 (Artigiani et al., 1999). Met is a well-known key contributor to
migratory cellular behavior in various cancers, including PC (Gentile et al., 2008).
These data suggest potential cross talk between SEMA5A, Plexin B3, and Met.
We used the above-mentioned accumulated knowledge to build the
rationale for our working hypothesis that interaction of SEMA5A with Plexin B3 is
necessary for downstream signaling events and regulation of cellular phenotypes
associated with cellular migration and metastasis in PC. Our data demonstrate that
SEMA5A induces increases cellular migration in PC cells and this effect is
mediated through Plexin B3 receptor. Furthermore, activation of Met receptor is
responsible for the SEMA5A-induced migration.
III. Results:
SEMA5A Treatment Induced Cellular Migration of PC Cells:
To evaluate the effect of SEMA5A on PC cells, we treated PC cell lines
AsPC-1 and T3M-4 with two different concentrations (50 ng and 100 ng) of
recombinant human SEMA5A. We utilized a scratch wound-healing and transwell
migration assay for evaluation of cellular migration and chemotaxis, respectively.
We observed a higher percentage of wound closure/migration in both AsPC-1 (Fig.
4.1A) and T3M-4 (Fig. 4.1B) cells on treatment with recombinant human SEMA5A
in comparison with their respective untreated control cells. We found a significant
difference in the wound closure ability of T3M-4 cells treated with 100 ng of
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SEMA5A in comparison with untreated cells (p = 0.0234). Similarly, we observed
chemotaxis of both AsPC-1 (Fig. 4.1C) and T3M-4 (Fig. 4.1D) towards SEMA5A.
A higher number of AsPC-1 cells migrated towards 50 ng and 100 ng in
comparison with the untreated control cells. Also, there was a significant difference
in the number of T3M-4 cells that had migrated towards 100 ng (p < 0.001) in
comparison with the untreated control cells. We also observed an increase (p =
0.0438) in cellular protrusion or cellular spreading of T3M-4 cells when treated with
50 ng of SEMA5A for 30 min (Fig. 4.1E).
SEMA5A Treatment Showed no Effect on Proliferation of PC cells:
Next, we evaluated the effect of SEMA5A on PC cells’ proliferation by using
the MTT assay. For this, we seeded PC cell lines AsPC-1, T3M-4 and CD18/HPAF
at two different cell densities and treated them with three different concentrations
(25 ng, 50ng, and 100ng) of recombinant human SEMA5A. We observed no
differences in cellular proliferation of AsPC-1(Fig. 4.2A), T3M-4 (Fig. 4.2B), and
CD18/HPAF (Fig. 4.2C) under treatment with different concentrations of SEMA5A
evaluated after 24 hours. Likewise, we observed no differences in the proliferation
of AsPC-1 seeded at 6000 cells per well (Fig. 4.2D) and at 2000 cells per well (Fig.
4.2E) evaluated at different time points for different concentrations of SEMA5A.
SEMA5A Mediates Cellular Migration in PC cells Through Plexin B3 Receptor:
Next, we generated stable Plexin B3 knockdown in T3M-4, and CD18/HPAF
cell lines (Fig. 4.3A). We evaluated migration (Fig. 4.3B), chemotaxis towards
SEMA5A (Fig. 4.3C) and scattering potential (Fig. 4.3D, E, F) of T3M-4-Control
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and T3M-4-shPlexin B3 cells by treating with recombinant SEMA5A protein. We
observed reduced effects of SEMA5A-induced migration and chemotaxis towards
SEMA5A on T3M-4-shPlexin B3 knockdown cells in comparison with the T3M-4
Control cells. Scattering of colonies (Fig. 4.3D) in both CD18/HPAF (Fig. 4.3E)
and T3M-4 (Fig. 4.3F) cells were higher in SEMA5A-treated cells in comparison
with their respective untreated Control cells. On the other hand, both CD18/HPAFand T3M-4-Plexin B3 knockdown cells showed a lower response to SEMA5Ainduced scattering of colonies.
SEMA5A Acts in a Plexin B3 Manner to Activate Met Signaling and Results in
Increased Migration:
Lastly, for evaluation of Met activation on treatment with SEMA5A, we
treated CD18/HPAF Plexin B3 knockdown and CD18/HPAF Control cells with 50
ng of SEMA5A protein. We probed cell lysates of untreated- and SEMA5A treatedCD18/HPAF-shPlexin B3 and CD18/HPAF-Control cells for phospho-Met
(Tyr1234/1235) and observed activation of Met in CD18/HPAF-Control cells on
treatment with 50 ng SEMA5A protein (Fig. 4.4A). However, the similar activation
of Met receptor was absent in SEMA5A-treated CD18/HPAF-shPlexin B3 cells
(Fig. 4.4A). Total cellular Met receptor levels remain unchanged with knock down
of Plexin B3 (Fig. 4.4B). We also evaluated chemotaxis towards SEMA5A of T3M4-Control and T3M-4-shPlexin B3 cells in presence and absence of 5 g Met
neutralization. We observed that Met neutralization leads to a decrease of 60% in
the T3M-4-Control cells chemotaxis towards SEMA5A (Fig. 4.4C). Furthermore,
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knockdown of Plexin B3 leads to a 30% decrease in chemotaxis towards SEMA5A
(Fig. 4.4C). However, knockdown of Plexin B3 along with Met neutralization leads
to a decrease of 90% chemotaxis towards SEMA5A (Fig. 4.4C).
IV: Discussion:
Previous reports on various cancer types have suggested both tumor
suppressive and oncogenic roles of SEMA5A (Purohit et al., 2014). In this study,
we have investigated the effect of SEMA5A on PC cells and whether the PC cells
respond to SEMA5A in a Plexin B3-dependent manner. We report that the
treatment of PC cells with SEMA5A acting as a ligand leads to an increase in
cellular motility and induction of scattering as well as having a chemotactic action
on different PC cells. Under this scenario, SEMA5A is acting in a forward signaling
manner. Our present results furthermore explain our previous findings that
SEMA5A enhances PC metastasis. Previously, we reported that overexpression
of SEMA5A in Panc-1 cell line resulted in enhanced in vivo migration or metastasis.
Likewise, Pan et al. reported that gastric cancer cells expressing SEMA5A could
promote invasion and metastasis by involving the PI3K/Akt/uPA signal
transduction pathway (Pan et al., 2009). This study does not define whether
SEMA5A increases invasion and metastasis in a forward or reverse manner.
However, in contrast to our findings, SEMA5A acting as a ligand in a forward
signaling manner by Plexin B3 receptor impedes cellular motility in glioblastoma
patients (Li et al., 2012a; Li and Lee, 2010).
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With the gain of knowledge that forward signaling of SEMA5A acting as a
ligand induces a migratory phenotype in PC cells, we went ahead to explore
whether ligand SEMA5A acts on PC cells using Plexin B3 as the interacting
receptor. Our in vitro studies suggest that SEMA5A induces migration and another
similar phenotype in PC cells in a Plexin B3-dependent manner. Various reports
based upon bioinformatics tools (Sadanandam et al., 2008) as well as functional
assays carried out using different cancer cells like glioblastoma and others also
suggest Plexin B3 as the interaction partner of SEMA5A (Artigiani et al., 2004; Li
et al., 2012b; Li and Lee, 2010; Pan et al., 2009). However, there are other known
receptors for SEMA5A as well. Using both in vivo and in vitro studies, Sema5A
and Sema5B have been shown to inhibit retinal neurite outgrowth through
PlexinA1 and PlexinA3 (Matsuoka et al., 2011). Thus, there is a need for future
experiments to gain a vision whether SEMA5A acts only through Plexin B3 in PC
cells or there are other receptors, that can mediate the effects of SEMA5A as well.
To furthermore explore signaling downstream of SEMA5A and Plexin B3,
we went ahead to neutralize the Met receptor. Plexins share high similarity with
Met and Recepteur d'Origine Nantais kinase (RON) members of the Scattered
Factor Receptor Family (Artigiani et al., 1999), and recently Conrotto et. al. showed
association of Met in receptor complexes formed by Plexin B2 and Plexin B3 but
not with other family members (Conrotto et al., 2004). In our experiments, we
observed activation of Met-mediated in a Plexin B3 manner (Fig. 4E). The
chemotaxis of PC towards SEMA5A was inhibited by more than 50% by
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neutralization of Met, suggesting Met activation as a necessary downstream event
in the SEMA5A-mediated migratory response. Since we were able to inhibit only
around 50% of the SEMA5A response, we cannot rule out the possibility of
SEMA5A engaging other kinase receptors for chemotaxis activity. Another
possibility is that Plexin B3 can elicit two different signaling pathways, one
dependent on the cytoplasmic domain of Plexins and other type is dependent on
engaging tyrosine kinase receptors such as Met for mediating cellular migration.
Moreover, other Semaphorins like Semaphorin 4D can also engage the Met
receptor using Plexin B1 as a receptor and can initiate invasive growth program
(Giordano et al., 2002) and angiogenesis (Conrotto et al., 2005).
In conclusion, our results provide novel insights into the role of SEMA5A
acting as a ligand in a forward manner on PC cells through Plexin B3 receptor.
Moreover, our results suggest a possible role involvement of SEMA5A/Plexin B3
with Met receptor thereby inducing a migratory response in PC cells.
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Figure 4.1: Treatment with SEMA5A induces migration of PC cell lines.
(A, B) Bar graph showing a higher percentage of distance migration in AsPC-1
(A) and T3M-4 (B) cell lines treated with 50 ng/mL and 100 ng/mL
concentrations of SEMA5A in comparison with untreated cells. Wound scratch
assay was used to evaluate migration. After placing a scratch followed by
SEMA5A treatment, 20 hours represent the endpoint of scratch evaluation.
Significant migration difference was seen between T3M-4 untreated and T3M4-100ng treated group (p = 0.0234). The values are a mean percentage of
migration ± SEM. The significance of the data was determined using one-way
ANOVA. (C, D) Box plot graphs are showing chemotaxis of AsPC-1 (C) and
T3M-4 (D) towards SEMA5A. Using transwell migration assay chemotaxis was
evaluated for different SEMA5A concentration (50 ng and 100 ng of SEMA5A
concentration and no serum medium as a control). The migrated cells were
counted in five independent fields (100x), using a Nikon Eclipse E800
microscope. The values are a mean number of migrated cells ± SEM. The
significant migrational difference was seen among AsPC-1 untreated, and both
50 ng and 100 ng SEMA5A-treated cells. Similarly, significant migration
differences were seen between T3M-4 untreated and T3M-4-100ng treated
group. The significance of the data was determined using the Kruskal-Wallis
test by ranks (*p ≤ 0.05, **p ≤ 0.01, *** p ≤ 0.001, nsp > 0.05). (E) Representative
images of cellular spread in presence and absence of SEMA5A (50ng). Images
were taken at 400x magnification using a Nikon Eclipse E800 microscope.Bar
graph showing an increase (p = 0.0438) in the ratio of the area of cellular
spreading with respect to the area of the nucleus of T3M-4 cells treated with 50
ng of SEMA5A for 30 min. Area of cellular spread and area of their respective
nucleus was calculated for 15 different SEMA5A-treated and -untreated cells
using Image J Software. The values are mean of the ratio of cellular area and
area of nucleus ± SEM. The significance of the data was determined using the
Mann-Whitney U Test.
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Figure 4.2: Treatment with SEMA5A has no effect on cellular proliferation
in PC cells.
(A, B, C) Line graph demonstrating no effect of SEMA5A treatment at three
different concentrations (25 ng, 50ng, and 100ng) on cellular proliferation of
AsPC-1 (A) T3M-4 (B) and CD18/HPAF (C) cells seeded at two different
concentrations. Cellular proliferation was evaluated after 24 hours of SEMA5A
treatment using the MTT assay. (D, E) Line graph demonstrating no effect of
SEMA5A treatment at three different concentrations (25 ng, 50 ng, and 100 ng)
on proliferation of AsPC-1 seeded at 6000 cells per well (D) and at 2000 (E)
cells per well and evaluated at different time points. The MTT assay was read
using BIO-TEX ELx-800 plate reader at 570 nm wavelength. The values are
mean of absorbance at 570 nm ± SEM. The significance of the data was
calculated using Two-way ANOVA test. Cell lines treated at different densities
were taken as Column Factor, and different SEMA5A concentration was taken
as Row Factor. No statistical differences were seen between Row Factor.
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Figure 4.3: Acting through Plexin B3 receptor, SEMA5A mediates cellular
migration.
(A) Western blot analysis of whole cell lysates of T3M-4 and CD18/HPAF
Control and Plexin B3 knockdown cells. Plexin B3 expression is downregulated
in Plexin B3 knockdown cells of T3M-4 and CD18/HPAF in comparison with
their respective Control cells. Quantification of the Plexin B3 protein by their
intensity of the bands with respect to their loading control GAPDH was
performed by Image J software. Bands were normalized on the T3M-4 or
CD18/HPAF Control cells. (B) Bar graph showing the percentage of migration
of T3M-4 Control and Plexin B3 knockdown cells with and without the treatment
with SEMA5A (50 ng). Control T3M-4 cells show a higher percentage of
migration (p ≤ 0.05) in response to the treatment of SEMA5A. T3M-4 Plexin B3
knockdown cells show no difference in the percentage of migration with the
treatment of SEMA5A. Wound healing assay is used for evaluation of migration
of the T3M-4 Control and knockdown cells. The values are a mean percentage
of migration ± SEM.The significance of the data was calculated using Two-way
ANOVA test. The PC Cell line in the presence and absence of SEMA5A were
taken as Row Factor and Control and Plexin B3 were taken as Column Factor.
(C) Box plot graph showing the chemotactic ability of the Control and Plexin B3
knockdown cells towards SEMA5A. The graph shows the higher chemotactic
ability of the T3M-4-Control cells towards the 50 ng (p ≤ 0.05) and 100 ng (p ≤
0.001) concentrations of SEMA5A. There is no significant difference in
migration of Plexin B3 cells treated with different SEMA5A concentration and
control. The migrated cells were counted in five independent fields (100x),
using a Nikon Eclipse E800 microscope The values are a mean number of
migrated cells ± SEM. The significance of the data was determined using
Kruskal-Wallis test by ranks (*p ≤ 0.05, **p ≤ 0.01, ***p ≤ 0.001, nsp > 0.05). (D)
Representative images of nonscattered and scattered colonies. Images are
taken at 200x magnification using a Nikon Eclipse TS100 microscope. (E, F)
Bar graph of scattering potential of Control and Plexin B3 knockdown cells
towards SEMA5A. The graph shows a higher scattering of colonies in both
T3M-4 (F), and CD18/HPAF (G) Control cells with SEMA5A treatment in
comparison with their respective untreated control cells. T3M-4- and
CD18/HPAF-Plexin B3 knockdown cells showed a significantly lower response
to SEMA5A-induced scattering of colonies. The percentage of scattered
colonies were counted in five independent fields (40x), using a Nikon Eclipse
E800 microscope. The values are a mean number of percentage of scattered
colonies ± SEM. The significance of the data was determined using KruskalWallis test by ranks (*p ≤ 0.05, **p ≤ 0.01, ***p ≤ 0.001, nsp > 0.05).
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Figure 4.4: SEMA5A activate Met signaling and results in increased
migration in a Plexin B3 dependent manner.
(A) Western blot analysis of whole cell lysates of Control and Plexin B3
knockdown CD18/ HPAF cells. The analysis shows Met activation on treatment
with SEMA5A in CD18/HPAF control cells. No increase in phospho-Met
(Tyr1234/1235) levels was observed in CD18/HPAF Plexin B3 knockdown with
50 ng of SEMA5A protein. Quantification of the phospho-MET(Tyr1234/1235)
protein by their intensity of the bands with respect to their loading control
GAPDH was performed by Image J software. Bands were normalized on the
T3M-4 Control or shPlexin B3 cells. (B) Western blot analysis showing no
change in total cellular Met receptor levels with knock down of Plexin B3.
Quantification of the Met protein by their intensity of the bands with respect to
their loading control GAPDH was performed by Image J software. Bands were
normalized on the T3M-4 Control cells. (C) Bar Graph showing inhibition of
chemotaxis towards SEMA5A of T3M-4 cells with cMET inhibition. Transwell
migration assay was utilized to evaluate chemotaxis of T3M-4- Control and
Plexin B3 knockdown cells towards SEMA5A in the presence and absence of
5 g Met neutralization. Considering the number of migrated T3M-4 cells
towards SEMA5A as 100%, Met neutralization led to 40% migration of T3M-4Control cells towards SEMA5A. Knockdown of Plexin B3 led to a 70% migration
of T3M-4 towards SEMA5A, and the combined effect of Plexin B3 knockdown
along with Met neutralization led to 10% of T3M-4 cells migrating towards
SEMA5A. The values are a mean number of percentage of migration ± SEM.
The significance of the data was determined using Kruskal-Wallis test by ranks
(*p ≤ 0.05, **p ≤ 0.01, ***p ≤ 0.001, nsp > 0.05.
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Figure 4.5: Schematic showing forward signaling of SEMA5A.
The representative schematic shows that SEMA5A as a ligand can act through
Plexin B3 receptor and activates MET tyrosine kinase receptor to trigger PC
cellular migration.
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Chapter 5
SEMA5A Maintains Epithelial Phenotype in Malignant PC Cells
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I. Abstract:
SEMA5A has been shown to be involved in organ-specific homing during
PC metastasis. We have also demonstrated that SEMA5A expression was higher
in well-differentiated tumors in comparison with poorly differentiated and normal
pancreas. In this report, we hypothesized that SEMA5A expression in malignant
PC cells regulates phenotypes associated with metastasis. We generated
SEMA5A knockdown T3M-4- and CD18/HPAF cells and assessed morphology,
motility, and expression of epithelial and mesenchymal markers. Control and
shSEMA5A cells were injected into the pancreas of nude mice to study primary
tumor growth and metastasis. Knockdown of SEMA5A leads to a transition from
epithelial to a mesenchymal phenotype, downregulation of E-Cad, an increased
expression of N-cad, and activation of the Wnt-signaling pathway. Moreover,
orthotopic injection of SEMA5A knockdown cells into nude mice resulted in a
significant increase in tumor burden and the liver metastases in comparison with
the Control cells. Furthermore, re-establishing SEMA5A expression with a
knockdown resistant mouse Sema5A in SEMA5A knockdown cells resulted in a
reversion to the epithelial state, as indicated by the rescue of E-Cad and N-Cad
expression. Collectively, our data demonstrate that SEMA5A expression
modulates cancer cell motility and aggressiveness by maintaining epithelial
phenotype in PC.
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II. Introduction:
Metastasis is responsible for 90% of cancer-associated deaths (Kitamura
et al., 2015). PC is the fourth leading cause of cancer-related deaths and is
projected to be the second leading cause by 2030 (Das and Batra, 2015; Rahib et
al., 2014). Due to the lack of any reliable early diagnostic markers and a higher
incidence of metastasis at the time of diagnosis, it has a dismal five-year survival
rate of only 6% (Das and Batra, 2015; Hingorani et al., 2003; Rahib et al., 2014;
Siegel et al., 2014). The National Cancer Institute reports nearly equal numbers of
estimated new cases and expected deaths in the United States from PC every
year, statistics that have not changed in almost 50 years (Rahib et al., 2014; Siegel
et al., 2014). Such epidemiological facts highlight the gravity of the situation,
making it necessary to explore further and understand the molecule(s) and
mechanisms(s) that lead to metastatic dissemination in PC.
A growing body of evidence now supports the role of various axon guidance
cue molecules, such as the semaphorins, in metastasis (Battistini and Tamagnone,
2016; Capparuccia and Tamagnone, 2009; Casazza et al., 2007; Kruger et al.,
2005; Muratori and Tamagnone, 2012; Neufeld et al., 2012; Rehman and
Tamagnone, 2013; Sakurai et al., 2012; Tamagnone and Comoglio, 2004;
Worzfeld and Offermanns, 2014). Semaphorins represent the largest family of
axon guidance cue molecule, which helps lay down the precise network of
neuronal circuits and blood vessels. These molecules play important roles in
pathological functions such as cellular migration (Casazza et al., 2007; Kruger et
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al., 2005; Tamagnone and Comoglio, 2004), angiogenesis (Neufeld et al., 2012;
Sakurai et al., 2012), and organ-specific homing of cancer cells (Sadanandam et
al., 2007). SEMA5A is a novel member of this family that is unique in having seven
thrombospondin repeats in its extracellular region, in addition to its characteristic
‘sema’ domain (Adams et al., 1996). SEMA5A can act as either a repulsive or an
attractive cue during cellular migration (Kantor et al., 2004). In the past decade,
SEMA5A has emerged as a promising molecule in cancer biology (Purohit et al.,
2014). Studies on various cancer types have suggested both tumor suppressive
and oncogenic roles for SEMA5A.
We have previously reported that SEMA5A expression was higher in welldifferentiated tumors in comparison with undifferentiated pancreatic tumors and
normal pancreas (Sadanandam et al., 2010b). Overexpression of SEMA5A in
Panc1 cells was sufficient to enhance metastasis (Sadanandam et al., 2012;
Sadanandam et al., 2010b). However, the functional significance of SEMA5A in
PC cells expressing higher endogenous levels of SEMA5A remained unexplored.
In the present study, we tested the hypothesis that knockdown of SEMA5A will
modulate phenotypes associated with tumor growth and metastasis in PC. To test
this hypothesis, we performed in vitro and in vivo assays to understand the effect
of SEMA5A deletion on PC metastasis. In contrary to our expectation, loss of
SEMA5A promoted tumorigenesis and enhanced metastatic potential of the PC
cell by regulating EMT.
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III. Results:
SEMA5A Knockdown Induces Mesenchymal Phenotype:
To understand the role of SEMA5A in PC, we knocked down SEMA5A
expression in T3M-4 and CD18/HPAF cells with short hairpin (sh)RNA-mediated
gene silencing. Liver metastasis-derived T3M-4 cells exhibit high SEMA5A
expression (Sadanandam et al., 2010b). Cells treated with shRNA of SEMA5A
(T3M-4-shSEMA5A) showed significant reduction of SEMA5A expression in
comparison with the non-targeting shRNA-treated T3M-4 control cells (Control) at
both the RNA, shown by RT-PCR (Fig. 5.1A), and the protein levels, as shown by
western blot analysis (Fig. 5.1B). Another evidence for the SEMA5A knockdown
came from immunofluorescence staining, which shows less SEMA5A staining at
the membrane in the T3M-4-shSEMA5A cells in comparison with the Control (Fig.
5.1C).
We observed a marked difference in morphology between SEMA5A
knockdown and vector control cells. Though heterogeneous, the T3M-4 and
CD18/HPAF Vector control cells demonstrated epithelial morphology with a
cobblestone-like appearance and closely apposed cell-cell junctions when plated
on plastic (Fig. 5.1D, 5.1E). In contrast, T3M-4-shSEMA5A and CD18/HPAFshSEMA5A cells had a mesenchymal morphology with spindle-like fibroblastoid
cells (Fig. 5.1D, 5.1E).
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Loss of SEMA5A Enhances Migration Ability:
The gain of mesenchymal phenotype leads to enhanced migration and
invasion ability of cells (Polyak and Weinberg, 2009; Thiery, 2002). We evaluated
motility of the vector controls and SEMA5A knockdown cells by scratch-wound
assay (Fig. 5.2A). We observed that SEMA5A knockdown cells had increased
motility in comparison with the Control in T3M-4 (p = 0.004), (Fig. 5.2B), and
CD18/HPAF cells (p = 0.001), (Fig. 5.2C). We also quantified lamellipodia and
filopodia-like protrusions in the Control and SEMA5A knockdown cells (Fig. 5.2D).
We found a significantly higher number of lamellipodia (p = 0.0079), (Fig. 5.2E)
and an increase in the number of filopodia in T3M-4-shSEMA5A cells (Fig. 5.2F).
The above data showing differences in morphology and motility ability of Controls
and T3M-4-shSEMA5A, CD18/HPAF-shSEMA5A cells suggest that loss of
SEMA5A in PC cells leads to loss of epithelial phenotype and a gain of
mesenchymal characteristics.
Loss of SEMA5A Induces EMT Markers and Activation of Wnt Signaling:
To characterize the observed morphological changes associated with the
knockdown of SEMA5A at the molecular level, we first evaluated the expression
of E-cad, a marker for epithelial characteristics. We performed Western blot
analysis and immunofluorescence to study the amount of E-cad expression and
its cellular localization respectively. Western blot analysis revealed decreased ECad expression in SEMA5A knockdown cells, in comparison with the Control cells
(Fig. 5.3A). Immunofluorescence analysis showed similar results with prominent
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plasma membrane staining of E-Cad in control cells, on the other hand, there was
less staining found for E-cad in T3M-4-shSEMA5A cells (Fig 5.3B).
Second, we went ahead to evaluate the expression of mesenchymal
markers in our Control and SEMA5A knockdown cells. We started with N-cad and
observed increased N-cad expression in the T3M-4-shSEMA5A cells by
immunofluorescence (Fig. 5.3C) as well as Western blot analysis (Fig. 5.3D) in
comparison with the Control cells. We observed more plasma membrane as well
as cytosolic staining for N-cad in the knockdown cells. Next, we evaluated the
mRNA expression levels of transcription factors Snail and Twist, which are known
suppressors of epithelial phenotype (Rosivatz et al., 2002). We observed that T3M4-shSEMA5A cells demonstrate higher levels of transcripts of SNAIL (p = 0.035)
(Fig. 5.3E) and TWIST (p = 0.034), (Fig. 5.3F) compared with the Control cells.
Furthermore, we observed a similar increase for the Snail (Fig. 5.3G) and Twist
(Fig. 5.3H) protein expression in the whole cell lysates of T3M-4-Control/shSEMA5A cells.
Using immunofluorescence, we observed increased intensity and a shift of
β-catenin localization from the plasma membrane to the cytoplasm (Fig. 5.4A) as
well as increased stabilization of β-catenin by Western blot (Fig. 5.4B) upon
SEMA5A knockdown. Furthermore, to confirm the presence of -catenin in the
nucleus, we went ahead and performed TOP-FLASH Wnt reporter assay. We
observed a significant increase in Wnt activity (p < 0.05) in T3M-4-shSEMA5A cells
in comparison with Control cells (Fig. 5.4C). Collectively, these data indicate that
128

epithelial PC cells expressing SEMA5A undergo EMT upon SEMA5A depletion
and this transition to the mesenchymal state results in activation of the Wnt
signaling pathway.
SEMA5A Knockdown Enhances Metastasis and Invasion:
In previous studies from our laboratory, we observed that ectopic overexpression of SEMA5A in poorly differentiated cells (with low expression of
SEMA5A) enhanced their metastatic potential upon orthotopic injection
(Sadanandam et al., 2010b). Thus, it was our expectation that SEMA5A
knockdown (in cells that endogenously express SEMA5A) would reduce their
tumorigenic and metastatic potential. However, given our in vitro observation that
SEMA5A knockdown promotes EMT, mesenchymal tumor cells are known to be
more mobile and hence more metastatic (Mani et al., 2008), thereby may promote
metastasis. To address in which direction this balance will tip, we injected SEMA5A
knockdown and Control T3M-4 cells (105) subcutaneously into the neck and flank
regions of athymic nude, female mice (n = 6). Tumor growth was monitored twice
weekly for three weeks. To our surprise, we did not observe a difference in tumor
incidence (Fig. 5.5A), growth (Fig. 5.5B) or morphology (Fig. 5.5C) between
SEMA5A knockdown and Control cells.
Furthermore, we injected 1X105 T3M-4-shSEMA5A or Control cells
orthotopically into athymic nude, female mice. Twenty-one days later, we sacrificed
the mice and examined for tumor growth and metastasis. We observed a
statistically significant difference in both organism weight (p = 0.034), (Fig. 5.5D)
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and tumor weight (p = 0.00159) (Fig. 5.5E) between T3M-4-shSEMA5A and
Control cells. Also, there was also a statistically significant difference in the number
and location of liver micrometastases (p = 0.0079), (Fig. 5.5F). Specifically,
SEMA5A knockdown cells metastasized to the liver and peritoneum with high
incidence (Fig. 5.G). It is important to understand that differences in metastasis
could also be a result of higher tumor burden in mice injected with T3M-4shSEMA5A cells. Before investigating further, we confirmed the maintenance of
SEMA5A knockdown in the tumors by performing immuno-histochemical staining
of SEMA5A in tumor sections (Fig. 5.5H).
Lastly, we investigated whether the difference in primary tumor burden is
due to proliferation differences between Control and SEMA5A knockdown cells.
Both the intensity of PCNA staining and the fraction of tumor cells positive for
PCNA were significantly higher in tumors in mice injected with T3M-4-sh-SEMA5A
cells than injected Control cells (Fig. 5.5F, 5.5G). H&E staining showed higher
cellular density in tumors of mice injected with SEMA5A knockdown cells than
Control cells (Fig. 5.5H). These data demonstrate that SEMA5A knockdown in
T3M-4 cells promotes tumorigenesis and metastatic potential in the pancreatic
microenvironment.
Knock-in of shRNA-Resistant SEMA5A Rescues Epithelial Phenotype:
To characterize the specificity of SEMA5A-induced mesenchymal
characteristics, we performed experiments to re-establish SEMA5A expression in
T3M-4-shSEMA5A cells and observed a reversal of the gain of mesenchymal
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characteristics. Hence, we transiently over-expressed knockdown resistant either
full-length murine Sema5A construct in T3M-4-shSEMA5A cells. Convincingly,
SEMA5A over-expression (Fig. 5.6A) reversed the morphological changes
observed upon knockdown of SEMA5A in T3M-4- cells (Fig. 5.6B). Furthermore,
the decrease in E-Cad expression was rescued (Fig. 5.6C) with the reestablishment of SEMA5A. Similarly the increase in expression of N-Cad (Fig.
5.6D) and enhanced stability of -catenin (Fig. 5.6E) seen in T3M-4-shSEMA5A
cells was lowered upon re-establishment of SEMA5A.
IV. Discussions:
In this study, we examined whether SEMA5A knockdown in PC cell lines
modulates tumor progression and metastasis. Unexpectedly, we observed
pronounced morphological changes associated with EMT upon SEMA5A
knockdown. Orthotopic pancreatic injection of SEMA5A knockdown cells resulted
in a significant increase in tumor weight and the number of distant metastases as
compared to Control cells. Furthermore, re-establishing SEMA5A expression in
SEMA5A knockdown cells resulted in a reversion of the mesenchymal to the
epithelial state (MET), suggesting a novel role for SEMA5A in the establishment
and maintenance of PC cells in the metastatic microenvironment through
maintenance of epithelial phenotype.
Metastatic progression requires a loss of contact with neighboring cells and
the gain of both extracellular matrix invasion and migration properties; this process
of morphogenetic reprogramming is termed "epithelial-mesenchymal transition" or
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EMT (Zavadil et al., 2008). EMT begins with the loss of the epithelial-like
characteristics, including loss of cell adherent junctional complexes, particularly
the adherent junction protein E-cad, epithelial intermediate filament cytokeratin as
well as cell polarization (Das and Batra, 2015; Yilmaz and Christofori, 2009;
Zavadil et al., 2008). These changes follow the acquisition of mesenchymal-like
characteristics, including a gain of the adherent junction protein N-cad, the
cytoskeletal element vimentin, and upregulation of transcriptional factors such as
zinc finger E-box binding homeobox 1, SNAlL, SLUG and TWIST (Rosivatz et al.,
2002; Zavadil et al., 2008). The increase in migration ability is also associated with
changes in polarized assembly of the actin cytoskeleton resulting in the formation
of protrusive and invasive structures (lamellipodia and filopodia) that help the cell
to navigate through the extracellular matrix (ECM) and through/into the vasculature
(Yilmaz and Christofori, 2009). Metastasis initiates when less aggressive epithelial
tumor cells within the primary organ acquire invasive and migratory abilities by
transitioning into mesenchymal cells (Chaffer et al., 2006; Polyak and Weinberg,
2009; Thiery, 2002). In doing so, such cells acquire the ability to pass into the
circulation and reach secondary organs. When tumor cells of mesenchymal
morphology reach a secondary site, they can revert to an epithelial state through
the reverse process of mesenchymal-epithelial transition (MET). Though the
classical view of metastasis was a late event during the progression of the disease,
recent studies with the use of mathematical modeling and genetically labeled
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mouse models of PC suggest early dissemination of cancer cells before the
formation of a primary tumor, as reviewed by Das and Batra (Das and Batra, 2015).
An important evidence for the role of SEMA5A in PC came from our
previous report demonstrating differential expression of SEMA5A in normal
tissues, well-differentiated tumors, and poorly differentiated tumors. Moreover,
exogenous expression of SEMA5A in the Panc1 cell line resulted in enhanced
migratory potential and metastasis of these cells without showing a significant
increase in the process of tumorigenesis, suggesting a tumor-promoting role of
SEMA5A in PC. Likewise, a study of samples from gastric carcinoma patients
illustrated elated expression levels of both SEMA5A and its receptor plexin-B3 in
primary gastric carcinoma and lymph node metastasis in comparison to the nonneoplastic tissue (Pan et al., 2009).
Surprisingly, our present observations are in contrast to our previously
reported data, since we observed increased in vitro motility, enhanced tumorigenic
and metastatic potential of T3M-4-shSEMA5A cells when implanted orthotopically
in nude mice in comparison with the Control cells. Furthermore, we observed a
marked difference in morphology between SEMA5A knock-down cells as
compared to their Control cells. Also, numerous studies have demonstrated that
E-Cad forms a complex at the plasma membrane with β-caten,in which is important
for maintaining the normal phenotype of epithelial cells (Fodde and Brabletz, 2007;
Heuberger and Birchmeier, 2010; Moon et al., 2004). Upon loss of E-Cad
expression, β-catenin translocates from the plasma membrane to the cytoplasm
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where it can either be phosphorylated by GSK-3β, and ultimately degraded, or
translocated into the nucleus. The relocalization of plasma membrane-bound βcatenin into the nucleus is both an indicator that epithelial cells are transitioning to
the mesenchymal state and a central component in Wnt-responsive gene
activation (Moon et al., 2004). These changes in morphology suggested the
induction of mesenchymal phenotype in T3M-4-shSEMA5A cells. Furthermore, in
vitro and in vivo behavior of T3M-4-shSEMA5A cells were in accordance, as
mesenchymal cells are known to demonstrate an enhanced potential for migration
and results in the formation of aggressive tumors. Other semaphorins, like
Semaphorin 7A in breast cancer cells (Allegra et al., 2012) and Semaphorin 3E
through the PlexinD1 axis (Tseng et al., 2011) in ovarian cancer cells are known
to mediate EMT. Li et al. have published similar findings on SEMA5A in
glioblastoma demonstrating, that the treatment of glioblastoma cell lines with
SEMA5A impaired cellular motility and promoted differentiation (Li et al., 2012b; Li
and Lee, 2010).
Our result suggests a functional role for SEMA5A in early dissemination of
cancer cells as well as the late stage dissemination of metastasis. Ectopic
expression in the poorly differentiated PC cell lines promotes migration and
metastasis without affecting the primary tumor burden, indicating parallel migration
of cancer cells at the distant site along with primary tumor formation. However,
loss of SEMA5A progresses a well-differentiated cancer cell to a poorly
differentiated state, representing metastasis as a consequence of the late stage of
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tumor progression (Fig. 5.7). Another possible explanation for the discrepancy that
both gains of SEMA5A in primary tumor cells or loss of SEMA5A in metastatic PC
cells result in higher metastasis may come from the involvement of two different
pathways. To describe, in short, Type 1 TSP repeats, a unique structural feature
of class 5 semaphorins, is known to activate the latent form of TGFβ, known player
of EMT induction. A Drosophila homolog of SEMA5A has been shown to increase
metastasis by activating the Dpp (TGFβ-like) pathway (Woodhouse et al., 2003),
suggesting increased SEMA5A will induce EMT. On the other hand in
glioblastoma, loss of SEMA5A leads to Rac1 activation results in increased
invasiveness, indicating that SEMA5A suppresses motility of cell (Li et al., 2012b;
Li and Lee, 2010). Thus, to completely understand the complex role of functional
SEMA5A in PC and metastasis, further experimentation and better model systems
are needed. Together with our previous data, these results suggest a contextspecific bi-functional role for SEMA5A: ectopic expression in the primary tumor
setting promotes cancer cell proliferation, migration, and metastasis, whereas
subsequent repression and re-expression in metastatic setting facilitates EMT and
MET, respectively, thereby endowing cancer cells with metastatic capacity.
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Figure 5.1: Confirmation of SEMA5A knockdown in PC cells and resulting
mesenchymal morphology.
(A) Bar graph showing fold change decrease in mRNA expression of SEMA5A.
HPRT is used as a control by RT-PCR analysis. The values are mean fold
changes ± SEM (bars) change calculated using T3M-4 transfected with a
pSUPER vector as a control. (B) Western blot analysis of cell lysates of Control
and

T3M-4-shSEMA5A

cells

confirming

decreased

SEMA5A

protein

expression with β-actin as a loading control. Quantification of the protein of
interest by the intensity of the bands with respect to their loading control was
performed by Image J software. Bands were normalized on the T3M-4-Control
cells. (C) Immunofluorescence of SEMA5A shows less staining of SEMA5A
(red) at the plasma membrane in T3M-4-shSEMA5A cells. Nucleus (blue) is
stained with DAPI and images were taken at 1000x magnification using a Nikon
Eclipse E800 microscope. (D, E) Morphological changes upon SEMA5A
knockdown. Cobblestone-like T3M-4-Control cells change to spindle shapes in
T3M-4-shSEMA5A cells. Images

were taken at 200x magnification.

CD18/HPAF-Control cells change to spindle shapes in CD18/HPAFshSEMA5A cells. Images were taken at 100x magnification using a Nikon
Eclipse TS100 microscope.
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Figure 5.2: Loss of SEMA5A increases migration ability in PC cells.
(A) Images showing scratch assay of Control and T3M-4-shSEMA5A at 0 hours
and 24 hours (100x magnification). (B) Quantitation of scratch assay using
ImageJ software showing a significant (p = 0.004) enhancement of migration in
T3M-4 SEMA5A knock-down cells. (C) Quantitation of scratch assay showing
a significant (p = 0.001) enhancement of migration in CD18/HPAF-1 SEMA5A
knock-down cells. The bars in the graphs represent mean percentage of the
distance of migration  SEM and the significance of the data is calculated using
using Student’s t-test. (D) Image showing staining of the actin cytoskeleton in
T3M-4-Control and T3M-4-shSEMA5A cells with increased number of
lamellipodium- and filopodium- like structures in SEMA5A knockdown cells.
Images were taken at 630× magnification using a LSM 710 Zeiss Confocal
Microscope. (E) Bar graph representing quantitation of lamellipodia in control
and knockdown cells showing an increase in the number of lamellipodia formed
(p = 0.0079) in knock-down cells. (F) Bar graph depicting quantitation of
filopodia, showing an increase in the number of filopodia in knock-down cells.
Five independent fields were used for quantification. The values in the graph
represent a number of Lamellipodia formation/ or filopodia per cell and the error
bars  SEM. The significance of the data is calculated using non-parametric
Mann-Whitney U test.
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Figure 5.3: Loss of SEMA5A induces EMT in PC cells.
(A) Immunofluorescence analysis shows lower E-cadherin expression on the
plasma membrane in T3M-4-shSEMA5A cells in comparison with Control cells.
Images were taken at 630× magnification using a LSM 710 Zeiss Confocal
Microscope. (B) Western blot analysis of whole cell lysates of T3M-4 Control
and SEMA5A knockdown cells shows a decrease in E-cadherin protein levels
with β-actin as a loading control in T3M-4-shSEMA5A in comparison with the
Control cells. (C) IF analysis of T3M-4 Control and SEMA5A knockdown cells
shows an increase in N-cadherin expression on the plasma membrane as well
as cytoplasm in T3M-4-shSEMA5A cells. Images were taken at 630×
magnification using a LSM 710 Zeiss Confocal Microscope (D) Western blot
analysis showing an increase in N-cadherin protein levels with -actin as a
loading control in T3M-4-shSEMA5A. E-cadherin and N-cadherin are stained
in red, and the nucleus is stained with DAPI (blue). (E, F) Bar graph showing
an increase in fold expression of transcription factors-SNAIL (p = 0.035) and TWIST (p = 0.036) in T3M-4-shSEMA5A in comparison with Control cells
evaluated using RT-PCR. The Ct values in RT-PCR were normalized to HPRT.
Values are mean Fold changes ± SEM (bars) of two experiments. (G, H)
Western blot analysis showing a similar increase in Snail and Twist protein
level. -Actin was used as loading control. The intensity of the bands in
Western blot analysis was quantified by Image J and was normalized with
respect to the T3M-4 Control cells.
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Figure 5.4: SEMA5A knockdown activates Wnt signaling in PC cells.
(A) Images showing immunofluorescence analysis of β-catenin localization in
Control and T3M-4-shSEMA5A cells. Images are taken at 200× magnification
using a Nikon Eclipse E800 fluorescent microscope. β-catenin staining is
depicted in red, and the nucleus is stained with DAPI in blue. (B) Western blot
analysis showing an increase in β-catenin protein levels in T3M-4-shSEMA5A
compared with Control cells.-actin is used as a loading control. The intensity
of the bands in Western blot analysis was quantified by Image J software and
was normalized with respect to the Control cells. (C) Bar graph showing an
increase in Wnt activity T3M-4-shSEMA5A than Control cells. TOP-FLASH was
utilized, and this assay was normalized to both FOP and Renilla vector
illustrating increased Wnt activity upon SEMA5A knockdown. The bars in the
graphs represent fold changes  SEM. *p < 0.05 using Student’s t-test.
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Figure 5.5: SEMA5A knockdown enhances tumor size and metastatic
potential.
(A) Incidence of the tumor, (B) presentation (as measured by H&E staining;
200× magnification; Nikon Eclipse E800 microscope) and (C) growth kinetics
of Control and T3M-4-shSEMA5A cells injected subcutaneously into nude mice.
Tumor volume was determined twice a week for three weeks. (D, E, F) Graph
showing increase in the average weight of the mice (p = 0.034), (D) the primary
tumor (p = 0.0159) (E) and number of liver metastases (p = 0.0079). (F) in mice
orthotopically injected with T3M-4 shSEMA5A cells in comparison with mice
injected with T3M-4-Control cells. (G) The chart shows the incidence of tumor
formation and metastasis. (H) SEMA5A expression (as measured by IHC
staining using 200× magnificationon a Nikon Eclipse E800 microscope) of
orthotopic pancreatic tumors from T3M-4 shSEMA5A and Control cells. (I) The
relative proliferation of tumor cells stained with PCNA (p = 0.023) in athymic
mice orthotopically injected with T3M-4-shSEMA5A cells in comparison with
those injected with Control cells. The error bars in the graphs presented in this
section represent  SEM. *p < 0.05 using Student’s t-test. (J) Representative
images showing PCNA staining of tumor cells in athymic mice orthotopically
injected with T3M-4-shSEMA5A cells in comparison with those injected with
Control cells. Images are taken at 200× magnification using a Nikon Eclipse
E800 microscope.
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Figure 5.6: Overexpression of shRNA-resistant SEMA5A rescues
epithelial phenotype.
(A) Western blot analysis showing SEMA5A in T3M-4-shSEMA5A and T3M-4shSEMA5A transfected with full-length mouse SEMA5A. GAPDH was used as
loading control. (B) Morphology of T3M-4-shSEMA5A and T3M-4-shSEMA5A
transfected with full-length mouse SEMA5A. Images are taken on 100x
magnification using Nikon Eclipse TS100 microscope. (C) E-Cadherin, Ncadherin and (D) -catenin protein expression with respect to loading control.
GAPDH was used as a loading control for -catenin, similarly -actin was used
as a loading control for E-cadherin and N-cadherin in T3M-4-shSEMA5A cells
and T3M-4-shSEMA5A cells transfected with full-length mouse SEMA5A. The
intensity of the bands in Western blot analysis was quantified using Image J
software and was normalized with respect to the T3M-4-shSEMA5A cells.
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Figure 5.7: The suggestive dual role of SEMA5A in PC.
This schematic representation depicts the potential role and expression of
SEMA5A in PC under the following conditions: (A) Pancreas and Liver under
normal homeostasis condition: no or low SEMA5A expression in Pancreas. (B)
Early stages of PC: a higher expression of SEMA5A in comparison with the
normal. Previous reports (Sadanandam et al., 2010a; Sadanandam et al.,
2012) suggest that ectopic expression of SEMA5A facilitates early
dissemination of PC cells, thereby establishing metastasis with no significant
difference in tumor burden between the Control and SEMA5A overexpressing
cells. The increase in angiogenesis can be attributed as one of the reasons for
the enhanced metastasis. (C) Late stages of PC: a decrease of SEMA5A
expression in comparison with early stages but the higher SEMA5A expression
in comparison with the normal. In the current chapter, knockdown of SEMA5A
expression leads to EMT, as which results in the formation of aggressive tumors
with higher tumor burden thereby resulting in higher metastasis.
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Chapter 6
SEMA5A preserves epithelial phenotype in PC cells by regulating crosstalk between Wnt and TGF signaling
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I. Abstract:
In the previous chapter of this dissertation, we observed that with the loss
of SEMA5A expression, cells exhibited a transition from an epithelial to
mesenchymal phenotype with a concomitant increase in cellular motility.
Furthermore, we observed a decrease in E-cad expression, nuclear translocation
of -catenin, and higher WNT activity. The aim of this section is to delineate the
mechanism associated with loss of SEMA5A-induced EMT. A Thrombospondin
repeat domain that is known to bind latent TGFmolecules is the characteristic
feature of a SEMA5A molecule. With this rationale, we first went ahead to evaluate
the changes in secretion of TGF2 ligands, since TGF is also one of the major
drivers of the process of EMT. We observed that loss of SEMA5A increased
TGF2 production. Higher Wnt signaling along with increased TGF2 production
delineates the loss of differentiation and epithelial markers. Moreover, we
observed that non-canonical TGF2/ PI3K/AKT-mediated inhibition of Glycogen
Synthase Kinase-3β (GSK3- is responsible for increased stability of-catenin
and SNAIL, thereby activating Wnt signaling in SEMA5A knockdown cells. Our
observations demonstrate that SEMA5A might have a potential role in maintaining
epithelial phenotype in PC cells by keeping cross-talk between Wnt and TGF
signaling under check.
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II. Introduction:
A plethora of current literature now extends our understanding of the
functions of semaphorins far beyond their initial characterisation as axon guidance
cues, such as in vascular and cardiac development, the immune system, cancer
progression, and in the pathology of various diseases and injury states
(Capparuccia and Tamagnone, 2009; Gu and Giraudo, 2013; Kolodkin et al., 1993;
Muratori and Tamagnone, 2012). Both during development as well as pathological
processes, Semaphorins and their receptors are well-recognized and major
regulators of cellular morphology and migration (Casazza et al., 2007; Tamagnone
and Comoglio, 2000; Tran et al., 2007). Despite the growing wealth of information
regarding varying biological functions of Semaphorins, many aspects of the
regulation of these functions remain unknown.
Semaphorin-induced cellular responses are variable, involving a complex
signaling network mediated through a multitude of possible receptors and signaling
molecules (Jackson and Eickholt, 2009; Zhou et al., 2008). The diverse range of
outcomes generated though semaphorin ligand and receptor complexes are often
cell type-dependent. Even within a given cell type, diverse outcomes are possible
in response to a particular semaphorin signal. The most important receptors for
semaphorins are members of the plexin family. The reverse signaling or
participation of semaphorin as a receptor in certain specific settings is also coming
into the light. Furthermore, current investigations also suggest that a cellular
response to semaphorin depends on the extracellular matrix composition in which
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production and presentation of semaphorins are occurring (Jackson and Eickholt,
2009; Kantor et al., 2004). Till date, our current understanding of semaphorin
signaling is largely dependent on studying several common molecular features of
semaphorin family through which this family mediates their responses.
Since Semaphorin-induced cellular responses are variable and work in a
context-dependent fashion, they have pleiotropic roles in cancer and can either
promote or inhibit tumor progression. Recent studies investigating different
semaphorin-initiated intracellular molecular mechanisms suggest crosstalk among
multiple signaling pathways including small GTPases, integrin, Mitogen-Activated
Protein Kinase (MAPK) and PI3K/AKT/GSK-3β axes (Kruger et al., 2005; Tran et
al., 2007; Zhou et al., 2008). All of the signaling axes mentioned above can lead
to rearrangements in cytoskeleton affecting cellular motility and migration.
In this part of the study, we wanted to delineate the molecular signaling
behind the loss of SEMA5A-induced mesenchymal phenotype and resulting
increase in motility. Our results demonstrate that SEMA5A might have a potential
role in keeping cross-talk between Wnt and TGF signaling under check for
maintaining an epithelial phenotype in the PC cancer cell.
III. Results:
Knock down of SEMA5A Upregulates TGF2 Liigands:
SEMA5A is a member of the Thrombospondin Repeat Superfamily (Fig.
6.1A) and can bind to TGF through “GGWPTW” motif but lacks the “KRFK” motif
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known to activate TGF(Fig. 6.1B)The “GGWPTW” motif is present in the
thrombospondin domain of SEMA5A-(Fig. 6.1C). With this rationale, we
evaluated the protein levels of the TGFβ2 ligands by using ELISA. The T3M-4shSEMA5A cells showed a marked increase in the expression of the TGFβ2 ligand
(Fig. 6.2A). Next, we evaluated nuclear localization of proteins homologous to
Drosophila

protein,

mothers

against

decapentaplegic

(MAD)

and

the

Caenorhabditis elegans protein SMA (derived from gene sma for small body size)
known as SMAD (SMA+MAD) in humans. Immunofluorescence was used for
nuclear localization of pSMAD2 levels. Our results demonstrate that the T3M-4shSEMA5A cells show no change in the percentage of cells having nuclear
localization of SMAD2 (Fig. 6.2B). Furthermore, Western blot analysis
demonstrated no change in p-SMAD2 and p-SMAD3 levels in the T3M-4shSEMA5A cell line (Fig. 6.2C).
Loss of SEMA5A Activates PI3K/Akt Signaling Pathway:
We next examined the activation of PI3K/Akt signaling pathway as a
possible mechanism of mesenchymal transition induced by knockdown of
SEMA5A. We observed no changes in the protein levels of PI3-K and Akt levels
between the Control and SEMA5A knockdown cells. However, p-PI3-K(Tyr458)
and p-AKT (Ser473) levels in SEMA5A knock down cells were found to be higher
than their respective control. We also went ahead to evaluate the levels of total
and p-GSK-3β (Ser9) in SEMA5A knockdown and the Control cells and observed
higher p-GSK-3in the SEMA5A knockdown cells (Fig. 6.3).
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IV. Discussions:
We observed that loss of SEMA5A leads to a marked difference in
morphology between SEMA5A knockdown cells and the respective Control cells,
demonstrating a transformation from epithelial to mesenchymal morphology with
increased cellular migration and resulting metastasis. For evaluation whether there
is an association between this transformation and EMT, we went ahead to analyze
EMT markers. We observed downregulation of epithelial marker E-cad that is a
key event in the induction of EMT. We also found upregulation of expression levels
of mesenchymal marker N-cad and transcription factor Snail, a known suppressor
of the epithelial phenotype. We also observed a shift in β-catenin localization from
the plasma membrane to the nucleus and higher expression of the β-catenin
protein resulting from SEMA5A knockdown by Western blotting, suggesting its
decreased degradation. Increased β-catenin in the nucleus can lead to the
activation of Wnt signaling pathway. By performing TOP-FLASH Wnt reporter
assay, we found the activation of Wnt signaling in our SEMA5A knockdown cells.
Thus, this chapter of the dissertation delineates our findings on the mechanism
associated with loss of SEMA5A-induced EMT.
Towards this aim, we first examined the role of TGF, one of the major
regulators of EMT (Katsuno et al., 2013; Wendt et al., 2009; Xu et al., 2009). For
instance, TGFβ strongly inhibits the growth of epithelial cells and hence is a potent
anti-tumor agent. However, TGFβ can also induce changes in transcriptional
activities (Derynck and Akhurst, 2007) and re-program epithelial cells into
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mesenchymal cells, leading to tumor metastasis and invasion. TGF, apart from
being major EMT regulator, also binds to thrombospondin repeat; a unique domain
of SEMA5A molecule (Adams and Tucker, 2000; Hayashi and Sakai, 2012;
Tucker, 2004; Woodhouse et al., 2003). The SEMA5A amino acid sequence
contains “GGWPTW”, the potential peptide through which SEMA5A can bind latent
TGF molecule. However, SEMA5A amino acid sequence lacks KRFK the peptide
known to activate TGF which implies that SEMA5A can bind to TGF molecule
but cannot activate it. We observed that loss of SEMA5A increased TGF2
production. Furthermore, to investigate the downstream pathways, the next
rational step was to study the SMAD pathway as through genetic studies in
Caenorhabditis elegans, and Drosophila revealed that Smads, are crucial players
in mediating the intracellular responses to TGFβ and its related factors (Derynck
and Zhang, 1996). Smads are transcription factors that constantly shuttle between
the

cytoplasm

and

the

nucleus.

TGFβ

receptors

activation

leads

to

phosphorylation of Smads that further get accumulated in the nucleus to regulate
target gene transcription. However, we observed no differences in nuclear
localization of p-Smad2 nor did the total cellular levels of p-Smad2 and p-Smad3
change.
Apart from Smad signaling, there is emerging evidence that suggests the
ability of TGFβ receptors to activate non-Smad pathways through either
phosphorylation or direct interaction. These non-Smad pathways include various
branches of Rho-like GTPase signaling, MAPK, and PI3K/ AKT pathways (Zhang,
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2009). Before going ahead to decide with which non-Smad signaling we should
start our exploration, we went back and re-analyzed our results described in the
last chapter. We observed stabilization of -catenin and Snail protein in our
knockdown cells. In the cytoplasm, phosphorylation of β-catenin and Snail occurs
by GSK-3β, which target these molecules for degradation (Patel and Woodgett,
2008; Sutherland, 2011). Thus, one possible mechanism in our SEMA5A
knockdown cells could be inhibition of GSK-3β, leading to stabilization of β-catenin
and Snail protein. With this rationale, we evaluated the inhibitory phosphorylation
of GSK-3β at Ser9, and observed increased phosphorylation of GSK-3β at Ser9
in SEMA5A knockdown cells in comparison with the Control cells with no changes
in the total protein level of GSK-3β.
Out of non-Smad pathways discussed at the beginning of this discussion,
PI3K/AKT signaling is known to mediate inhibitory phosphorylation on GSK-3β
(Cross et al., 1995). With this knowledge, we made the choice of exploring the
PI3K/AKT pathway first and observed increased phosphorylation of AKT at Ser473
and PI3K at Ser458, indicating activation of these proteins in SEMA5A knockdown
cells in comparison with the Control cells. There were no significant differences in
the total protein levels of PI3K and AKT proteins in the Control and knockdown
cells.
Our obtained results suggest one possible mechanism associated with the
loss of SEMA5A-induced EMT that is through a noncanonical TGF pathway
mediated EMT. According to this mechanism, the thrombospondin repeat domain
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of SEMA5A molecule keeps latent activation of TGF2under inhibition. With the
loss of SEMA5A, TGF2 gets secreted and activates noncanonical PI3K/AKT
pathway. The activation of the PI3K/AKT pathway leads to inhibition of GSK-3β,
which in turn results in stabilization of β-catenin and Snail protein. Stabilization of
β-catenin leads to active translocation of β-catenin from the cytoplasm into the
nucleus, furthermore leading to activation of WNT signaling. On the other hand,
stabilization of Snail protein leads to the repression of mRNA transcription of Ecad. This repression of E-cad mRNA transcription leads to a decrease in the Ecad protein levels as well leading to induction of EMT (Fig. 6.4). However, our
suggested mechanism needs further validation by utilizing neutralization antibody
against TGF2 and inhibitors against PI3K and AKT.
Finally, our data demonstrate that loss of SEMA5A initiates crosstalk
between TGF and WNT signaling. These observations also demonstrate the link
between SEMA5A and both TGF and WNT pathways that cooperate towards
epithelial de-differentiation leading to EMT. Our data leads to better understanding
of the Semaphorin-mediated signaling pathway that leads to different in vitro
processes like migration, dispersion, invasion and in vivo progression of
metastasis.
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Figure 6.1: SEMA5A is a member of the Thrombospondin Repeat 1
Superfamily and has motif “GGWPTW” known to bind TGF but does not
have “KRFK” motif known to activate TGF
(A) Domain structure of representative members of the Thrombospondin
Repeat 1 Superfamily. SEMA5A is a member of this Superfamily. Represented
in yellow diamonds, are Thrombospondin Repeats. (B) Different peptide
signatures through which Type 1 (represented in yellow), Type 2 (represented
in oval green) and Type 3 (represented in blue striped box) Thrombospondin
repeats bind to different molecules like Heparan sulfate proteoglycans (HSPG),
TGF and, CD36 and many other molecules through the extracellular region.
(C) Represented amino acid sequence is of human SEMA5A. Highlighted
amino acid sequence in blue represents the sequence of thrombospondin
domain-containing seven Type 1 repeats. The amino acid sequence
“GGWPTW” shown in red represents the potential peptide through which
SEMA5A binds latent TGF molecule. However, SEMA5A does not contain the
KRFK peptide known to activate TGF molecule that implies that SEMA5A can
bind to TGF- molecule but cannot activate it.
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Figure 6.2: Loss of SEMA5A activates TGF
(A) Bar graph showing higher TGF2 secretions in T3M-4 SEMA5A knockdown
cells in comparison with T3M-4-Control cells, evaluated using ELISA for TGF2.
(B) Immunofluorescence showing no differences in pSMAD2 nucleus
localization in T3M-4 Control and shSEMA5A knockdown cells. Phospho
SMAD2 (Ser465/467) is depicted in red and nuclei are depicted in blue. Images
were taken at 200x magnification using a Nikon Eclipse E800 Microscope.(C)
Western blots show no changes in levels of p-SMAD2(Ser465/467) and pSMAD3(Ser423/425)

in T3M-4-shSEMA5A and T3M-4 Control cells. The

intensity of the bands in Western blot analysis was quantified by ImageJ using
-actin as an internal control and was normalized with respect to the T3M-4
Control cells.
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Figure 6.3: Loss of SEMA5A activates the non-canonical PI3K/AKT
pathway.
Western blots on whole cell lysates showing an increase in levels of p-PI3K
(Ser 458), p-AKT(Ser 473) and GSK3Ser9 in T3M-4-shSEMA5A in
comparison with T3M-4 Control cells, suggesting activation of non-canonical
PI3K/AKT activation. GAPDH serves as a loading control. Western blots show
no change in the total protein levels of PI3K, AKT, and GSK3 The intensity of
the bands in Western blot analysis was quantified by Image J using GAPDH as
an internal control and was normalized with respect to the T3M-4 Control cells.
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Figure 6.4: Suggested mechanism demonstrating how the loss of
SEMA5A can trigger TGF activation, resulting in EMT and initiation of
Wnt signaling.
Representative schematic demonstrates the proposed mechanism of
regulation of TGF by SEMA5A. The thrombospondin repeat domain of
SEMA5A molecule keeps latent activation of TGF2under inhibition. With the
loss of SEMA5A, TGF2 gets secreted and activates non-canonical PI3K/AKT
pathway. The activation of PI3K/AKT pathway leads to inhibition of GSK-3β,
which in turn results in stabilization of β-catenin and Snail protein. Stabilization
of β-catenin leads to active translocation of β-catenin from the cytoplasm into
the nucleus, further leading to activation of WNT signaling. On the other hand,
stabilization of Snail protein leads to the repression of mRNA transcription of Ecadherin.

This repression of E-cadherin mRNA transcription leads to a

decrease in the E-cadherin protein levels, as well as leading to induction of
EMT.
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Chapter 7
Loss of Plexin B3 Increases Cellular Motility and Metastasis in PC
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I. Abstract:
Plexins are the primary receptors for semaphorins, guidance cue ligands,
which regulate cellular adhesion and the motility of different cell types in response
to their ligand. A growing body of evidence now supports the roles of various
semaphorins and plexins in cancer progression by their involvement in
pathological processes such as angiogenesis, cellular migration, and metastasis.
The significantly worse prognosis of PC is largely attributable to the metastatic
nature of the disease. Recent studies associate expression of SEMA5A with higher
metastasis in PC. SEMA5A was identified as a cell adhesion molecule critical for
organ-specific homing of cancer cells in PC. However, the expression and role of
the SEMA5A receptor, Plexin B3, is yet to be investigated in PC. In the present
study, we investigated the role of Plexin B3 receptor by knocking down Plexin B3
expression in PC cell lines T3M-4 and CD18/HPAF. Knockdown of Plexin B3 cells
resulted in a change of epithelial phenotype to mesenchymal state with enhanced
in vitro cellular migration. Plexin B3 knockdown cells also showed impaired colony
formation on a three-dimensional growth factor-reduced Matrigel Matrix. We
observed similar in vivo results with higher metastasis and lower tumor burden in
Plexin B3 knockdown cells injected orthotopically into nude mice in comparison
with the Control cells. We also went ahead to investigate the expression of Plexin
B3 in the disease progression model of PDX-Cre-Kras(G12D) mice and observed
low expression of Plexin B3 in normal mice with higher Plexin B3 expression in
initial time points (20 weeks) in comparison with later time points. Our observations
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indicate that Plexin B3 inhibits cellular motility and maintains epithelial phenotype
of PC cells. The mechanism behind this phenotype needs further investigation.
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II. Introduction:
PC is often diagnosed at an advanced stage that makes surgical resection
of tumor unfeasible, and thus PC is the fourth leading cause of cancer death in the
United States (Siegel et al., 2017). Also, most cases present themselves with
regional lymph nodes and liver secondary tumor growth, indicating the spread of
cancer to nearby and distant places by the process called metastasis (Das and
Batra, 2015). One of the important events for the process of metastasis is the gain
of migration ability. Both physiological and pathological cell migration is regulated
by guidance clue molecules, which can be membrane bound or secreted. The
semaphorin and their receptor plexin families of proteins are neuronal guidance
molecules characterized by the presence of a conserved ‘sema’ domain of ~ 500
amino acids in the N-terminal region (Yazdani and Terman, 2006). Recent
literature reports aberrant expression as well as dysregulated signaling of these
molecules in cancer progression (Biankin et al., 2012; Neufeld et al., 2005).
Previous reports from our laboratory provide evidence for a realizable role
of SEMA5A, a novel member of this family of proteins, in the pathogenesis of PC
metastasis (Sadanandam et al., 2012; Sadanandam et al., 2007; Sadanandam et
al., 2008). Using an in vivo phage display library and integrated computational
analysis, we identified SEMA5A as a putative cell adhesion molecule involved in
organ-specific homing during PC metastasis (Sadanandam et al., 2007). We have
demonstrated that the Panc1 cell line with overexpression of SEMA5A acquired
enhanced metastatic potential when implanted orthotopically in a nude mouse
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(Sadanandam et al., 2010b). These data point towards a possible involvement of
SEMA5A in PC metastasis. For better understanding the downstream signaling
events and regulation of cellular phenotypes associated with SEMA5A in PC
metastasis, it is necessary to characterize the role of its receptor Plexin B3 in PC.
The Plexins family is comprised of four subfamilies named Plexin A, B, C,
and D and were initially identified as molecules that mediate cell adhesion (Gu and
Giraudo, 2013; Janssen et al., 2010). Both membrane-bound and secreted form
of Plexins are known, and they can mediate autocrine or paracrine signaling by
binding to their respective semaphorin (Negishi et al., 2005). Interestingly, Plexins
can act as ligands as well as receptors for semaphorins. Plexins are known to
mediate an auto-inhibitory effect in the absence of the ligand by their extracellular
“sema” domain. Their intracellular region contains two highly conserved GTPase
activating proteins (GAP like domains) and a linker region with no intrinsic GAP
activity. Additional to the above domains, Class B plexins, also have a C-terminal
consensus sequence that interacts with PDZ domains. Thus, our primary objective
for the current study was to characterize the role of SEMA5A receptor Plexin B3 in
PC cell lines. Knocking down of Plexin B3 in T3M-4 and CD18/HPAF cells resulted
in increased in vitro and in vivo migratory potential. These effects were found to be
associated with the induction of mesenchymal phenotype.

174

III. Results:
Loss of Plexin B3 Enhances In vitro Cell Migration:
We stably downregulated the expression of Plexin B3 in T3M-4 and
CD18/HPAF cells, as described previously in Chapter 5. We observed a marked
difference in morphology between CD18/HPAF-shPlexin B3 cells (Fig. 7.1A)
compared to their Control cells. The CD18/HPAF- Control cells demonstrated
clump-like structures with closely placed cells when plated on plastic. In contrast,
CD18/HPAF-shPlexin B3 cells had a mesenchymal morphology with spread and
spindle-like fibroblastoid cells. Next, we evaluated the effect of Plexin B3
knockdown on cellular migration and invasion. In vitro cellular migration was
evaluated by performing wound healing and transwell migration assay. Consistent
with our morphological data, in vitro cell migration was higher in both Plexin B3
knockdown cells in comparison to the Control cells (Fig. 7.1B, 1C, 1D).
We also evaluated invasion properties of these cells by using the Transwell
invasion assay. In this assay, the well was coated with Matrigel and both
CD18/HPAF- and T3M-4 Control cells and their respective Plexin B3 knockdowns
were evaluated. We found an increase in the invasion with Plexin B3 knockdown
in CD18/HPAF cells (Fig. 7.1E), however, in T3M-4 cells there was less invasion
of Plexin B3 knockdown cells in comparison with the Control (Fig.7 1F), but this
difference was not statistically significant.
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Plexin B3 Knockdown Results in Lower Tumor Burden:
CD18/HPAF-shPlexin B3 or CD18/HPAF-Control cells were injected
orthotopically into athymic female nude mice. Mice were sacrificed at 34 days after
injection. We observed a lower tumor weight (p = 0.0159) (Fig. 7.2A, 7.2B, 7.2C)
in mice injected with CD18/HPAF-shPlexin B3 cells in comparison with mice
bearing CD18/HPAF-Control cells. We did not see any difference in the average
weight of mice from these groups (Fig.7 2D). Furthermore, H and E evaluation
revealed lower necrosis, and higher infiltration of tumor microenvironment cells in
tumor burden of CD18/HPAF-shPlexin B3-injected mice in comparison with tumors
of mice injected with CD18/HPAF-Control cells (Fig.7 2E). We also observed the
lack of colony formation of Plexin B3 knockdown cells on three-dimensional matrix
compared with their respective Control cells (Fig. 7.2F). However, in vitro analysis
of proliferation of CD18/HPAF- and T3M-4 Control cells and their respective Plexin
B3 knockdowns showed no proliferation differences (Fig.7 2G).
Loss of Plexin B3 Enhances Metastasis:
Evaluation of metastases in mice injected with CD18/HPAF-shPlexin B3
showed a higher incidence of liver, peritoneal cavity and lymph node metastasis
and incidence of ascites (Fig. 7.3A). There was a significantly higher number of
micrometastases (p = 0.0259) in the liver of mice injected with CD18/HPAFshPlexin B3 cells compared with mice bearing the CD18/HPAF-Control cells (Fig.
7.3B, C, D).
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Differential Plexin B3 Expression in PC Tumor Progression KC model:
To evaluate Plexin B3 expression during PC disease progression,
pancreatic tissues derived from KC mice sacrificed at different time points (10, 20,
30 and 50 weeks) were used to generate a progression model. We observed low
expression of Plexin B3 in the normal pancreas, derived from the control PDX-cre
mice. However, in KC mice there was an increase in Plexin B3 expression
beginning at 10 and 20 weeks of age (Fig. 7.4). This expression decreased in the
tumors of mice at 30 and 50 weeks age, which represents fully developed PDAC.
No Change in EMT Markers Occurs With Loss of Plexin B3:
We evaluated EMT markers in Control and Plexin B3 knockdown cells. We
observed no change in the expression of E-cad, N-cad, -catenin, and Snail at
protein levels in T3M-4-(Fig. 7.5A,) or CD18/HPAF- (Fig. 7.5B) shPlexin B3 cells
and their respective Control cells.
IV. Discussion:
In this study, we have investigated the role of SEMA5A receptor Plexin B3
in PC progression and metastasis. An important piece of evidence for the role of
SEMA5A in PC metastasis came from our previous report demonstrating the
functional role of SEMA5A (Sadanandam et al., 2010a; Sadanandam et al., 2007;
Sadanandam et al., 2008; Sadanandam et al., 2010b). However, the role and
function of the SEMA5A receptor Plexin B3 are yet to be explored in PC. To
investigate the role of Plexin B3 in PC, we went ahead to evaluate the in vitro and
in vivo effect of downregulating Plexin B3 on the biological behavior of T3M-4 and
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CD18/HPAF PC cell line. We observed enhanced in vitro migration with the loss
of Plexin B3. Supporting our in vitro assay results, the knock-down of Plexin B3
resulted in enhanced metastatic potential of CD18/HPAF cells when implanted
orthotopically in nude mice.
Furthermore, we observed a marked difference in morphology between
CD18/HPAF-shPlexin B3 cells compared to their Control cells. We also observed
the lack of three-dimensional colony formation in Plexin B3 knockdown cells.
However, we did not observe any significant difference in in vitro proliferation of
Plexin B3 knockdown cells and their Control counterparts. Our in vitro functional
assays explain our in vivo observation of lower tumor burden in mice injected with
Plexin B3 knockdown cells. Loss of colony formation rather than defective
proliferation appears to be the cause of this lower tumor burden. Our observations
are supported by the recently published unrecognized function of the SemaphorinPlexin B2/B1 system as a crucial regulator of mitotic spindle orientation that is
important in the establishment and maintenance of epithelial architecture during
morphogenesis and repair (Xia et al., 2015).
We also observed an initial increase in Plexin B3 expression in tumor
progression model of KC mice, however, in advanced stages of the tumor, loss of
Plexin B3 expression was observed. Similar results were reported by Balakrishnan
et al. showing somatic mutations in Plexin B3 in PDAC cases (Balakrishnan et al.,
2009). Through functional assays in cellular models, the group demonstrated that
c.1613G, R538H mutation in the extracellular domain of Plexin B3 prevented
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binding of the ligand Sema5A, These missense mutations result in loss of Plexin
B3 function. Likewise, the mRNA and protein expression levels of Plexin B3 were
found to be downregulated in hepatocellular carcinoma samples in comparison
with the corresponding adjacent non-cancerous tissue (Liu et al., 2015). This group
further

elucidated

the

correlation

between

Plexin

B3

expression

and

clinicopathological data by performing IHC on 84 hepatocellular carcinoma
archived specimens and reported lower expression level of Plexin B3 in tumor
tissues in comparison with the corresponding adjacent non-cancerous tissue.
We also evaluated motility and invasiveness of our Plexin-B3 knockdown
and their respective Control cells using different in vitro functional assays. We
observed higher in vitro cellular motility for both CD18/HPAF-shPlexin-B3 and
T3M-4-shPlexin-B3 cells in comparison with their respective Control cells. We
observed a similar increase in the number of T3M-4-shPlexin-B3 migrated cells
than T3M-4-Control cells using Transwell migration assay and also an increase in
the invasiveness of CD18/HPAF-Plexin-B3 knockdown cells in comparison with
the CD18/HPAF-Control. Our in vitro functional assays explains our in vivo
observation of higher incidence of metastasis in different organs of mice injected
with CD18/HPAF-Plexin-B3 knockdown cells in comparison with the group of mice
injected with CD18/HPAF-Control cells. Similarly, we observed a higher number of
macro, and micro metastases in the liver of CD18/HPAF Plexin-B3 injected mice
than in CD18/HPAF-Control injected mice. This increase in incidence and number
of metastasis is not a consequence of the difference in primary tumor burden but
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increase invasiveness and migration properties of Plexin-B3 knockdown cells. Our
results suggest that loss of Plexin-B3 enhances escape of a tumor cell from the
main tumor by increasing motility and invasiveness of the cancer cell, thereby
resulting in low tumor burden with high metastasis.
However, to delve further into the molecular mechanism regarding the change of
morphology in Plexin B3 knockdown cells, we examined these cell lines for the
expression of markers of epithelial and mesenchymal phenotypes. Our data
demonstrated no changes in epithelial and mesenchymal markers with the loss of
Plexin B3. In conclusion, for the first time in our knowledge, our work provide novel
insights into the role of SEMA5A receptor Plexin-B3 in PC tumor growth and
metastasis. Loss of Plexin-B3 accelerates the process of metastasis in PC by
enhancing the migration and invasion ability of these cells.
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Figure 7.1: Knock down of Plexin B3 enhances in vitro migration of
Pancreatic Cancer (PC) cells.
(A) Representative images of the morphology of CD18/HPAF Control and
Plexin B3 knockdown cells. Images show morphological differences in
CD18/HPAF Control cells with clustered cells changing to flat and spindle
shaped with knockdown of Plexin B3. Images were taken at 100x using a Nikon
Eclipse TS100 microscope. (B, C) Bar graphs are showing higher in vitro
migration of Plexin B3 knockdown cells in CD18/HPAF (p < 0.0001) (B) and
T3M-4 (p = 0.0162) (C) in comparison with their respective Control cells using
wound scratch assay. The values in the graph represent the percentage of
distance migration, and the error bars represent SEM. Statistical p-value was
calculated using Student’s t-test. (D) Box plot analysis shows higher in vitro
migration of Plexin B3 knockdown cells in T3M-4 (p = 0.0078) in comparison
with the Control cells using Transwell migration assay. The values represent
number of migrated cells and error bars in the box plot represent SEM.
Statistical p-value was calculated using non-parametric Mann-Whitney U-Test.
(E, F) Bar graph shows the number of invaded cells in the Control and Plexin
B3 knockdown in CD18/HPAF cells and T3M-4 cells. Bar graphs show a higher
number of cells invading through the matrix in CD18/HPAF-Plexin B3 (p =
0.057). Knockdown cells in comparison with the respective control cells. T3M4 Plexin B3 knockdown cells show a lower number of invaded cells in
comparison with the Control cells (p = 0.067). The values in the graph represent
the number of invaded cells, and the error bars represent SEM. Statistical pvalue was calculated using non-parametric Mann-Whitney U-Test.
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Figure 7.2: Knockdown of Plexin B3 results in low tumor burden.
(A) Representative image of tumors formed from the injection of CD18/HPAFControl and CD18/HPAF-shPlexin B3 cells in athymic nude mice. The image
shows the higher tumor size of CD18/HPAF-Control cells’ derived tumors in
comparison with CD18/HPAF-shPlexin B3 derived tumors. (B) The chart is
showing tumor incidence, average tumor weight and average mice weight of
mice injected with CD18/HPAF-Control and CD18/HPAF-shPlexin B3. (C)
Graph showing tumor weight of five different mice in each CD18/HPAF-Control
and CD18/HPAF-shPlexin B3 group and their average. The graph shows lower
tumor burden of CD18/HPAF-shPlexin B3 group in comparison with
CD18/HPAF-Control cells (p = 0.0162). (C) Graph showing weights of five mice
in each CD18/HPAF-Control and CD18/HPAF-shPlexin B3 group and the
average mouse weight. The graph shows no differences in mouse weight of
CD18/HPAF-shPlexin B3 group and CD18/HPAF-Control cells (p = 0.562). The
values in the graph represent tumor weight or mice weight, and error bars in
the graphs represent SEM. Statistical p-value was calculated using nonparametric Mann-Whitney U-test. (E) Representative images of H and E
staining of primary tumor burden formed by the CD18/HPAF-shPlexin B3 and
CD18/HPAF-Control cells. Images show lower necrosis and higher infiltration
of tumor microenvironment cells in tumor burden of CD18/HPAF-shPlexin B3
in comparison with CD18/HPAF-Control tumors. Images were taken at 100x
magnification using a Nikon Eclipse E800 microscope. (F) Representative
images of colonies formed by CD18/HPAF-Control and CD18/HPAF-shPlexin
B3 cells in three-dimensional Matrigel matrix. Images show stained nucleus
(DAPI) of the cells in a colony demonstrating a lack of ability of CD18/HPAF
Plexin B3 cells to form compact colonies in comparison with their respective
Control cells. Images are taken at 100x magnification using a Life EVOS FL
fluorescence microscope. (G, H). Line graphs are demonstrating no difference
in the cellular proliferation of the Plexin B3 knockdown and Control cells of
CD18/HPAF (G) and T3M-4 (H). The MTT assay was read using BIO-TEX ELx800 plate reader at 570 nm wavelength. The values are mean of absorbance
at 570 nm ± SEM. The significance of the data was calculated using Two-way
ANOVA test. Cell lines treated at different densities were taken as Column
Factor, and different Control and Plexin B3 knockdown cells were taken as Row
Factor. No statistical differences were seen between Row Factor.
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Figure 7.3: Knockdown of Plexin B3 enhances metastasis.
(A) Chart of the percentage of metastasis incidence at different sites like liver,
lymph, peritoneum, and percentage of ascites formation in mice injected with
CD18/HPAF-Control and CD18/HPAF-shPlexin B3 cells. The chart shows
higher metastases incidence in mice injected with CD18/HPAF-shPlexin B3 in
comparison with the mice injected withCD18/HPAF-Control cells. (B)
Representative images of H and E staining of the liver showing a higher number
of micrometastases in the liver. Images were taken at 100x using a Nikon
Eclipse E800. (C, D) Graph showing number of micro (C) and macro (D)
metastases in five different in each CD18/HPAF-Control and CD18/HPAFshPlexin B3 group and the average number of metastases. The graphs shows
higher no micro (p = 0.029) and macro (p = 0.089) metastases formation in
group of mice injected with CD18/HPAF-shPlexin B3 cells in comparison with
the group injected with CD18/HPAF-Control cells (p = 0.0162). The values in
the graph represent the number of macrometastasis or micrometastasis in liver
per mice. The error bars in the graphs represent SEM. Statistical p-value was
calculated using non-parametric Mann-Whitney U-Test.
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Figure 7.4: Plexin B3 Expression progressively increases in the
developing cancerous lesions of KC mice and decreases in the cancerous
lesions at a later time point.
Representative images of Plexin B3 immunohistochemistry performed on
progression model derived from tumors of KC mice (n = 5) at different ages (20
weeks, 30 weeks and 50 weeks). The pictorial graph demonstrates first a
progressive increase in qualitative Plexin B3 expression followed by a decrease
in Plexin B3 expression at 30- and 50- weeks age mice that represent fully
developed PDAC. The normal pancreas of 50- week Pdx1-cre mice shows low
Plexin B3 expression. The images were taken at 100x magnification using a
Nikon Eclipse E800 microscope.
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Figure 7.5: Knockdown of Plexin B3 shows no difference in expression of
epithelial and mesenchymal markers.
(A, B) Western blot analysis of whole cell lysates of T3M-4 and CD18/HPAF
Control and Plexin B3 knockdown cell lysates. Western blot analysis shows no
change in the expression of E-cadherin, N-cadherin, -catenin, and Snail at
protein levels in T3M-4- (A) CD18/HPAF-shPlexin B3 cells (B) and their
respective Control cells. The intensity of the bands in Western blot analysis was
quantified by Software ImageJ using -actin as an internal control and was
normalized with respect to the T3M-4 or CD18/HPAF Control cells.
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Chapter 8
Major Conclusions and Future Directions
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SEMA5A in PC: a perspective:
Like other cancers, PC is also a complex disease with loss of control in the
regulation of normal physiological processes, ranging from cell proliferation to
restricted cell migration. The growth and spread of the cancer cells rely not only
on the genetic and epigenetic alterations in the tumor cells but also take active
advantage of the dysregulation in the microenvironment resulting as a
consequence of the tumor.
However, unlike other cancers, there are limited advances made in the
treatment of PC with its incidence almost equivalent to mortality. As described
previously in Chapter 1, targeting metastasis is the real challenge for improving
the mortality rate in PC. Since the process of metastasis is a cascade of several
steps, efforts are being made to identify targets that are mediating different steps
of this process. Out of all the steps of metastatic cascade, the last step of
metastatic colonization represents an important step in PC. The reason being
already mentioned earlier that mostly at the time of diagnosis, cancer has already
metastasized to distant organs. Hence it is believed that cancer cells have already
undergone through all the steps of the metastatic cascade. Thus, any target that
can inhibit establishment of metastasis furthermore will improve the survival time
of the patient. These are unconventional targets that do not a prime rapid division
of tumor cells to inhibit tumor growth but limit their escape from the primary tumor
to distant organs. Their drawback could be that they cannot be used alone but in
combination therapy only.
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One such emerging unconventional target belongs to the family of guidance
cue ligands, such as Semaphorins and their receptors Plexins, Semaphorins and
their receptor signaling are known to play an important role during the development
of different organ systems such as nervous, immune, cardiovascular, and others.
However, their expression is found to decrease in the adult. Considering their wide
expression pattern and role in development, it is distinctly possible that their
dysregulated signaling will impact different aspects of cancer biology.
Recent reports reveal defective axon guidance signaling in the pancreatic
genome (Biankin et al., 2012). However, expression of semaphorins in PC cannot
be treated as the driver mutation and their aberrant signaling is a consequence of
the accumulation of other multiple gene mutations. Several previously published
reports from our laboratory have suggested the potential of SEMA5A as a
“molecular target” for PC therapies. In general, SEMA5A has higher cell surface
expression in the cancer cells in comparison with the normal pancreas. To
understand the functional aspect, we overexpressed two forms of SEMA5Amembrane-bound and secretory and observed higher metastasis with both forms
of SEMA5A overexpression. However, the resulting primary tumor burden from the
orthotopic injection of control and SEMA5A overexpressing cells in the nude mice
showed no difference with membrane-bound SEMA5A and lower primary tumor
with a secretory form of SEMA5A.
The purpose of the research presented in this dissertation was to
furthermore investigate our previous findings and delineate the function and
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pathological expression of SEMA5A in the malignant PC tumor cells and
metastatic establishments. In this chapter, I will summarize the major findings and
conclusions of all the chapters compiled in this dissertation. Also, in the later
section, I will discuss the questions that are still unanswered and possible
experiments to investigate these questions in future.
Major Findings:
When and where is SEMA5A expressed in PC?
i) In human as well as in mice, the normal pancreas either shows low or no
SEMA5A expression; however, in PC tissues, their expression is located
mostly on malignant ducts.
ii) Surrounding tumor stroma is not positive for SEMA5A expression. Analysis
of SEMA5A expression between different stages of PC revealed no
significant difference.
iii) SEMA5A expression was significantly higher in well-differentiated and
moderately differentiated tumors in comparison with poorly/undifferentiated
tumors.
iv) Upregulation of the SEMA5A expression in primary tumor can be seen from
20-weeks old KC mice, and there is a gradual increase in later time points.
v) SEMA5A expression was positive in different metastatic sites of humans as
well as KPC mice. Metastatic sites such as liver showed higher SEMA5A
expression in comparison with the primary tumor.
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vi) SEMA5A expression is seen in PDAC (exocrine) as well as PanNET
(endocrine tumors) and their respective metastasis.
vii) The gain of copy number variation of SEMA5A is seen for pancreatic
adenocarcinoma and PDAC cases.
viii) SEMA5A expression, whether low or high, correlates with poor survival of
PC cases. However, high SEMA5A shows better survival for PC patients
than a low expression of SEMA5A.
What is the function of SEMA5A as a ligand on PC tumor cells?
i) SEMA5A induces cellular migration, chemotaxis, and scattering in PC cells.
ii) SEMA5A mediates its effect through the Plexin B3 receptor.
iii) SEMA5A through Plexin B3 leads to catalytic activation of MET receptor.
What is the function of endogenous SEMA5A expression on tumor cells?
i) Downregulation of endogenous SEMA5A in differentiated cells leads to a
mesenchymal phenotype.
ii) Downregulation of SEMA5A upregulates EMT markers.
iii) Downregulation of SEMA5A increases migratory and invasive phenotype
both in vivo and in vitro.
iv) Overexpression of SEMA5A in SEMA5A knockdown cell rescues the
epithelial phenotype, suggesting a possible role of SEMA5A in metastatic
colonization and establishment at the metastatic site.
What can be possible pathways affected by the endogenous SEMA5A molecule in
PC?
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i) Increase in Wnt activation.
ii) Increased TGF2 levels with no changes seen in SMAD pathway.
iii) Activation of PI3K/AKT pathway and inhibition of GSK3
What is the function of endogenous SEMA5A receptor-Plexin B3 on PC tumor
cells?
i) Loss of Plexin B3 leads to the acquisition of mesenchymal morphology with
increased invasiveness and migration.with impaired colony formation on 3dimensional matrix.
ii) No change in EMT markers.
iii) Loss of Plexin B3 shows an increase in metastasis even with lower primary
tumor burden.
iv) Upregulation of the Plexin B3 expression in primary tumor can be seen in a
20-weeks old KC mice, but there is a gradual decrease in expression at
later time points.
Summary and Major Conclusion:
Based on several observations made by downregulating the expression of
SEMA5A and its putative binding partner Plexin B3 in PC cell lines and studying
the effect of this downregulation by different in vitro or in vivo assays, we
summarize the role of SEMA5A in PC progression in the following paragraphs:
Healthy pancreas shows no expression of SEMA5A, but during initiation of
PC due to factors unknown, the SEMA5A expression is upregulated on the surface
of oncogenic cells. The upregulation of SEMA5A molecule is also suported by a
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gain of copy number of SEMA5A in Pancreatic adenocarcinoma cases. The
upregulated SEMA5A molecule is cleaved by some metal metalloproteases, and
the secreted SEMA5A can attract endothelial cells, leading to angiogenesis as well
as causing the migration or escape of cancer cells from the primary tumor by acting
through Plexin B3 receptor. The proliferating tumor cells loses SEMA5A and Plexin
B3 expression and thereby proceeds from differentiated to undifferentiated status.
Loss of SEMA5A expression with disease progression is also supported by
analysis of SEMA5A expression in human patients, TMA by IHC. Furthermore,
loss of both SEMA5A and Plexin B3 increases the invasive and migratory
phenotype of cancer cells, which leads to an increase in metastasis formation.
On the other hand, tumor cells reaching different metastatic sites
furthermore upregulates the expression of SEMA5A molecule to regain epithelial
state and undergoes establishment. In accordance, we have observed an increase
in SEMA5A expression at metastatic sites in comparison with the primary tumor in
human patients as well as in the KPC mouse model.
Thus, in the general scenario of PC cases where primary tumors have
already metastasized to nearby and distant organs, SEMA5A expression should
be positive in the metastatic establishments, whereas the advanced primary tumor
should have low SEMA5A expression. In conclusion, based on the results
generated in this study we conclude that SEMA5A play multifaceted roles during
PC progression and establishment of metastasis. SEMA5A represents a potential
candidate for targeting metastatic establishments, but whether the same holds true
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for primary tumors still needs further investigation. The summary and major
conclusions of this dissertation are presented in a pictorial form in Figure 8.1 and
Figure 8.2, respectively.
Future Directions:
What are the factors that regulate the expression of SEMA5A and Plexin B3?
Currently, we do not have any knowledge regarding regulatory controls of
SEMA5A. However, there is evidence that links SEMA5A with inflammation such
as the report of neutrophil infiltration in mastitis resistance (Sugimoto et al., 2006),
induction and secretion of Th1/Th17 cytokines with SEMA5A treatment and
increased SEMA5A expression in serum of rheumatoid arthritis patients (Gras et
al., 2014). Likewise, we have also seen upregulation of Interleukin-8 with
overexpression of secretory SEMA5A in PC cells (Sadanandam et al., 2012). The
link between inflammation and cancer is well known but whether inflammation or
cancer is the causative agent and the other of the two is the effector is yet to be
established (Coussens and Werb, 2002). Taken together these findings suggest
that inflammation and SEMA5A may connect through a feedback response, and
possibility needs to be investigated in future. In the future, regulation of SEMA5A
can be investigated using in silico analysis of promoter and initiation area, 5′rapid
amplification of cDNA ends, reporter-gene assays, gel shift and co-expression
experiments.
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Plexin B3 transcriptional regulation was analyzed, and a 234 base pair
region upstream of Plexin B3 exhibited promoter activity (Tiismus et al., 2008)
using the above mentioned techniques. Further analysis of this region showed
binding sites for myeloid zinc finger protein 1 and neurogenin 3. Out of the two,
Neurogenin-3 is expressed in endocrine progenitor cells and is required for its
development in the pancreas and intestine (Wang et al., 2006). In normal adult
human, Neurogenin 3 (NGN3) is expressed by 2-10% of acinar and duct cells.
Further investigations are needed to understand the regulation of Plexin B3 by
Neurogenin 3 in PC.
Which metalloproteinase can cleave transmembrane SEMA5A and make it
secretory?
The mechanism by which SEMA5A is cleaved from the PC cell surface is
still unknown. However, A disintegrin and metalloproteinase 17 (ADAM-17) has
been shown to be involved in the release of secreted SEMA5A in rheumatoid
arthritis patients (Gras et al., 2014). A recent report provides evidence of aberrant
expression of the proteolytically active ADAM17 in advanced precursor lesions
(PanIN-3) (Ringel et al., 2006). Hence, it will be interesting to investigate whether
active ADAM 17 is involved in cleaving SEMA5A from the PC cell surface and their
combined activity on PC metastasis.
Elucidation of reverse signaling for the molecule of SEMA5A.
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In chapter1 we have discussed different types of possible signaling between
SEMA5A and Plexin B3 molecule. In this dissertation, we were only able to
delineate forward signaling of SEMA5A as a ligand and Plexin B3 as a putative
receptor. Since secretion of Plexin B3 is also known in nature, it will be interesting
to understand signaling through cytoplasmic domain of SEMA5A.
Binding Partners for SEMA5A
We have yet to define the domains of SEMA5A that are critical for binding
to Plexin B3 receptor. Also, our current results do not rule out the potential of NRP2
as a binding partner of secretory SEMA5A and need investigation in future.
Similarly, known neuronal SEMA5A receptors Plexin A1 and A3 also needs
evaluation in the context of PC.
Defining the Role of Stage-Specific SEMA5A Expression in PC:
To define the stage-specific role of SEMA5A, we need to generate a
knockout model of SEMA5A in the pancreas of genetically engineered PC
progression mouse model such as Pdx1-cre; KrasG12D under an inducible control
system. Future directions are also represented in a pictorial form in Figure 8.3.
There is an urgent requirement for new molecular targets for improving
therapeutics and biomarkers in PC. In this dissertation, we evaluated the
expression and function of SEMA5A in PC pathology. The results presented here
clearly suggest a dual role of SEMA5A in PC. Overexpression of SEMA5A
increases metastasis by enhancing the angiogenesis step of metastatic cascade
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while downregulating the expression of SEMA5A leads to tumor promotion by
mediating mesenchymal transition. We believe that these results will serve as a
guiding light for future research, but to reach an unequivocal conclusion, further
research efforts in the field of semaphorins in cancer are essential.
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Figure 8.1: Summary of the project “The role of SEMA5A in PC
progression and metastasis”.
Schematic representation summarizing the role of SEMA5A in PC. (A)
SEMA5A expression analysis in different PC mouse models and human patient
samples in a TMA suggests an increase in SEMA5A expression with the
progression of PC with low or no expression in normal pancreas. (B) SEMA5A
is also present in different PC metastatic sites like liver, spleen, and others. In
pancreatic neuroendocrine

cases, metastatic sites show

furthermore

upregulation of SEMA5A expression in comparison with the primary tumor. (C)
The increase in SEMA5A during PC progression facilitates migration of PC
cells. SEMA5A acts as a ligand and acts through Plexin B3 receptor and
activates MET tyrosine kinase receptor for triggering PC cellular migration. (D)
However, endogenous expression both SEMA5A and Plexin B3 maintains the
epithelial phenotype of a cancer cell that can aid the establishment of
macrometastasis at metastatic sites.
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Figure 8.2: Major conclusions of the project “The role of SEMA5A in PC
progression and metastasis”.
Schematic diagram summarizing pro- and anti- tumor effects of SEMA5A in
PC. (A) Loss of expression of both SEMA5A and its receptor Plexin B3 leads
to an invasive phenotype in PC cells and results in higher metastasis
suggesting that SEMA5A and receptor Plexin B3 maintains epithelial
phenotype of the PC cell and keeps metastasis under check. (B) However,
expression of SEMA5A, especially the secreted form, also results in higher
metastasis, suggesting a dual effect of SEMA5A on PC. (C) Lastly, SEMA5A
as a ligand induces angiogenesis, as well as increases cancer cell migration,
thereby resulting in higher metastasis and demonstrating pro-tumor effects of
SEMA5A in PC.
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Figure 8.3: Future directions of the project “The role of SEMA5A in PC
progression and metastasis”:
Schematic diagram presenting questions which we have yet to answer. (A)
The factors which can regulate the expression of SEMA5A and are these
factors differentially present in primary tumor and metastatic sites. (B) Which
proteases can cleave transmembrane SEMA5A and make it secretory in PC
environment. (C) Apart from Plexin B3, Plexin A1 and Plexin A3 are also known
to mediate the effects of SEMA5A in non-pancreatic tissues. Neuropilin 2
(NRP2) can act as a co-receptor for secretory Semaphorins. Thus, receptor
Plexin A1 and Plexin A3 as well as possibly Neuropilin as co-receptor for
SEMA5A in PC needs further evaluation. (D) Reverse signaling of SEMA5A
acting as a receptor also needs an evaluation. (E) Lastly, stage-specific
expression of SEMA5A needs evaluation to determine whether we can use
SEMA5A at prevention or intervention or a regression stage.
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